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ABSTRACT 
Plasma triacylglycerols (TG) are elevated in diabetes, metabolic syndrome, 
obesity, and dyslipidemia. Very-low density lipoprotein (VLDL) is the main plasma 
carrier of TG and the direct metabolic precursor of low-density lipoprotein (LDL), 
the main carrier of plasma cholesterol and the major causative risk factor for 
atherosclerosis. Binding of LDL to heparan sulfate on the arterial wall initiates 
retention and modifications of LDL in the arterial intima, triggering atherosclerosis. 
Studies presented in this dissertation show that variations in TG levels and 
lipoprotein binding to heparin, a model for heparan sulfate, alter the structural and 
biochemical stability of VLDL and LDL, and increase their atherogenic potential. 
The molecular consequences of variations in the lipoprotein TG content and 
LDL-heparin binding were determined by combining heparin affinity 






techniques. Remodeling of human VLDL and LDL by thermal denaturation was 
used to mimic key aspects of lipoprotein remodeling in vivo. Our studies revealed 
that increasing the TG content in VLDL promotes changes in the lipoprotein size 
and release of the exchangeable apolipoproteins. Similarly, increased TG content 
in LDL promotes lipoprotein remodeling and fusion. Additionally, an increase in TG 
content increases lipoprotein susceptibility to oxidation and lipolysis, thereby 
promoting the generation of free fatty acids that augment fusion. Consequently, 
TG-induced destabilization may be a general property of plasma lipoproteins.  
Our studies showed that binding to heparin initiates irreversible pro-
atherogenic remodeling of human LDL. As a result of heparin binding, LDL showed 
decreased structural stability and increased susceptibility to hydrolysis and fusion. 
Further, phospholipid hydrolysis and/or glycation of LDL (as occurs in diabetes) 
increased the proteolytic susceptibility of apolipoprotein (apo)B (the major 
apolipoprotein of VLDL and LDL) and its heparin binding affinity. LDL derived from 
hyperglycemic patients with type-2 diabetes, became particularly destabilized 
following heparin binding causing apoB fragmentation and LDL fusion.  In 
summary, binding to heparin alters apoB conformation and triggers pro-
atherogenic LDL modifications including proteolysis, lipolysis and structural 
destabilization. Furthermore, phospholipid lipolysis and glycation of LDL in vitro 
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Chapter 1.   Introduction 
1. Lipoproteins and their major classes 
Lipoproteins are macromolecular complexes of lipids and proteins whose key 
function is to solubilize lipids and transport them to and from somatic tissues. 
Lipoproteins orchestrate metabolism of plasma lipids; they deliver dietary lipids to 
peripheral tissues and remove excess phospholipids and cholesterol, which is 
essential for maintaining cellular lipid homeostasis. Lipoprotein dysfunction, 
whether from particle instability or defects in lipoprotein metabolism, is often 
associated with various pathologies including obesity, metabolic syndrome, 
diabetes and atherosclerosis (Olson 1998, Mahley et al., 1984).  
Lipoproteins are classified according to their densities, which provide the basis 
for their separation by ultracentrifugation. The seven classes of lipoproteins 
differing in density, from low to high, are chylomicrons, chylomicron remnants, very 
low-, low-, intermediate-, high-density lipoproteins and lipoprotein (a) (Table 1.1) 
(Feingold & Grunfeld, 2018). These classes of lipoproteins differ in particle size: 
larger lipid-rich particles are less dense than the smaller protein-rich particles 
(Table 1.1). Lipoproteins also differ in their lipid and protein composition, their 
biosynthetic pathways, their function and their final destination (Olson, 1998). This 
dissertation focuses on two major lipoprotein classes, very low-density lipoproteins 
(VLDL) and low-density lipoproteins (LDL). 
Despite their biochemical, structural and functional differences, lipoproteins 






particle has a central core of apolar lipids, mainly CEs and triacylglycerols (TG). 
This hydrophobic core is surrounded by an amphipathic monolayer with a 
hydrophilic surface, which is essential for solubilization and transport of otherwise 
insoluble lipids. This surface monolayer consists of polar lipids, mainly 
phospholipids and free (unesterified) cholesterol. These complexes are stabilized 
















Triglycerides apoB-48, apoC, 









VLDL 0.930- 1.006 30-
80 








LDL 1.019- 1.063 18- 
25 
Cholesterol apoB-100 




Lp (a) 1.055- 1.085 ~30 Cholesterol apoB-100, apo(a) 
 
Table 1.1 Major lipoprotein classes: particle sizes, densities, and major lipids and 







1.2 Lipoproteins: Major -pathways of lipid transport in plasma 
Lipoproteins are involved in three major pathways of lipid transport in plasma: 
(1) the transport of dietary or exogenous lipids, (2) the transport of hepatic or 
endogenous lipids and (3) reverse cholesterol transport (Olson, 1998; Kwiterovich, 
2000). 
The exogenous pathway starts with the incorporation of dietary lipids into TG-
rich chylomicrons in the intestine (Figure 1.1). Following secretion, plasma 
chylomicrons are metabolized by lipoprotein lipase (LpL) in muscle and adipose 
tissue. Chylomicron metabolism releases free fatty acids, which are subsequently 
metabolized by muscle and adipose tissue. The resulting chylomicron remnants 
are then taken up by the liver in a receptor-mediated mechanism (Kwiterovich, 
2000). 
The endogenous pathway begins in the liver with the synthesis of apoB which 
binds TG and CEs to form and secrete VLDL (Figure 1.1). TG and CEs are derived 
primarily from endogenous synthesis in the liver. Once in plasma, TG in VLDL are 
hydrolyzed by LpL to release free fatty acids, and IDL particles are formed. IDL are 
either taken up by the liver or further metabolized to LDL. LDL, the major carrier of 
plasma cholesterol, provides cholesterol to peripheral tissues in an LDL receptor 







Figure 1.1 Overview of lipoprotein metabolism. Figure adapted from Shepherd 
(2001).  
 
 Reverse cholesterol transport begins with apoA-I secretion by the liver 
and intestine. ApoA-I binds to ATP-binding cassette transporter A1 (ABCA1) to 
promote cholesterol and phospholipids efflux to form nascent, discoidal HDL. 
Nascent HDL promotes further cholesterol efflux from peripheral cells (Figure 1.1).  
Cholesterol is then esterified by the lecithin:cholesterol acyltransferase, leading to 
the formation of mature spherical HDL that contain a core of CEs and a small 
amount of TG. Mature HDL deliver their lipid cargo to the liver in a process 
mediated by HDL scavenger receptor class B, type 1 (SR-BI) (Braun et al., 2002). 








excess cholesterol from peripheral cells and transport it to the liver for excretion 
via bile (Gordon et al. 1989; Toth et al. 2013). This pathway is called reverse 
cholesterol transport. 
In addition to reverse cholesterol transport, HDL play other beneficial roles, 
including anti-inflammatory and anti-oxidant actions. Therefore, HDL generally 
serve a cardioprotective role. Indeed, plasma levels of HDL cholesterol inversely 
correlate with the risk of atherosclerosis, and low HDL is an independent risk factor 
for atherosclerosis and type II diabetes (Navab et al., 2011).  The current 
consensus is that not only quantity, but specific qualities of these heterogeneous 
particles are important (Ferretti et al., 2006; Navab et al., 2011; Lamarche et al., 
1999).  
In contrast to HDL, apoB-containing lipoproteins are pro-atherogenic and LDL 
are called the “bad cholesterol”. In fact, plasma levels of LDL cholesterol and, 
particularly, apoB are the strongest causual predictor of the risk of atherosclerosis 
(Feig, 2012; Camejo et al., 1998; Skålén et al., 2002). This pro-atherogenic 
property of LDL and its metabolic precursor, VLDL, stems from the major function 
of LDL in delivering cholesterol to peripheral cells (Camejo et al., 1998).  Since 
LDL and VLDL are the focus of this dissertation research, metabolism of these 








Apolipoproteins are essential for the integrity of the lipoprotein assembly. They 
act as structural scaffolds that confer curvature to the surface monolayer, which is 
necessary to sequester lipid cargo in its core. Apolipoproteins are necessary for  
lipoprotein stability, yet they serve more than just a structural role. Apolipoproteins 
help guide the formation of lipoproteins and act as ligands for lipoprotein receptors 
or enzymes involved in lipoprotein metabolism (Mahley et al., 1984).  
The apolipoproteins are amphipathic molecules, with hydrophobic faces 
interacting with the lipids and polar faces interacting with the solvent (Mahley et 
al., 1984; Kwiterovich, 2000). Based on their solubility, the apolipoproteins are 
subdivided into two major groups, exchangeable and nonexchangeable. The 
exchangeable apolipoproteins are water-soluble and can reversibly bind to the lipid 
surface; hence, they can exchange among lipoprotein particles. In contrast, the 
nonexchangeable apolipoprotein, apoB, is water-insoluble and is permanently 
associated with its parent lipoprotein particle (Kwiterovich, 2000, Goldstein & 
Brown, 1977).  
1.3.1 The exchangeable apolipoproteins 
1.3.1.1 Overview of structural properties  
The exchangeable apolipoproteins range in size from 8 kD to 70 kD (Table 
1.2) (Bessendine et al., 2011).  This protein family has evolved from the common 
ancestral gene related to apoC-I (Fullerton et al., 2004), and family members share 






sequences contain 11/22-mer tandem repeats that encode for amphipathic α-
helices (Figures 1.2 and 1.3) (Segrest et al., 1992). Apolar faces of these helices 
either interact with lipids in the lipid-bound state, or are packed against each other 
in the lipid-free state. 
The exchangeable apolipoproteins are dynamic molecules that undergo 
major conformational changes upon transfer between the lipid-free and lipid-bound 
states, which is required for their function in binding to and releasing from the 
lipoprotein surfaces (Gursky, 2005; Saito et al., 2004; Weers & Ryan, 2003). These 
dynamic conformations present a challenge for high-resolution structural analyses. 





















Table 1.2 Apolipoproteins associated with lipoproteins. Compiled following 
(Sundaram & Yao, 2012; Yang & Qin, 2015, de Silva et al., 1990) 
 
the last decades, a number of atomic structures of apolipoproteins have been 
determined using solution NMR and X-ray crystallography. These include high-
resolution X-ray crystal structures of the globular, lipid-free N-terminal domain of 
human apoE (Hatters et al., 2006) and the C-terminally truncated human apoA-I, 






bound dimer (Mei & Atkinson, 2011) (Figure 1.2, panel A). NMR structures of 
several apolipoproteins and their fragments, including modified full-length apoE, 
apoC-I, apoC-II and apoC-III, have also been determined in solution (Wang et al., 
2002) or in detergent micelles (Figure 1.3, panels A and B) (Zdunek et al., 2003; 
Rozek et al., 1999; Okon et al., 2002; Cushley & Okon, 2002; Raussens et al., 
2003; Fan et al., 2003); the latter mimic the lipid-bound protein state. These 
structures have provided clear insights into how apolipoproteins confer curvature 
to the lipoprotein surface and act as structural scaffolds. They also clarified how 
apolipoproteins interact with their functional ligands such as lipid transporters and 
lipoprotein receptors. 
Despite these advances, detailed structural studies of lipoproteins present 
a major challenge due to biochemical and conformational heterogeneity of these 
particles. To-date, the only atomic structure of a lipoprotein is a solid-state NMR 
structure of a model HDL particle comprised of a truncated form of apoA-I and a 
model phospholipid, palmitoyl oleoyl phosphatidylcholine (POPC) (Figure 1.2, 
panel B) (Bibow et al., 2016). This structure verifies the “double belt” model of HDL 
where two antiparallel copies of apoA-I form a helical double belt around the 
particle perimeter, stabilized by dozens of salt bridges and a zipper-like pattern of 








Figure 1.2 Molecular structures of apoA-I. Ribbon diagrams are colored from 
the N-terminus to the C-terminus (blue to red). 
(A) X-ray crystal structure of lipid-free C-terminally truncated apoA-I (residue 
fragment 1-185) solved at 2.2 Å resolution (PDB ID: 3R2B) (Mei & Atkinson, 2011).  
(B, C) Top and side views of the atomic structure of a model discoidal HDL 
comprised of truncated apoA-I and POPC, determined by NMR (PDB ID: 2N5E) 
(Bibow et al., 2017) 
 
1.3.1.1 Major exchangeable apolipoproteins on VLDL and their functional 
roles 
The apoCs (C-I, C-II, and C-III) are the smallest human apolipoproteins that 
circulate mainly on VLDL, and are also found as minor proteins on HDL and other 
lipoproteins. The apoCs are important for the metabolism of TG-rich lipoproteins; 









plasma factors that remodel these lipoproteins in vivo (Das & Gursky, 2015). 
ApoC-I inhibits CE transfer protein, apoC-II is a physiological activator of LPL, 
while apoC-III is an inhibitor of the enzymeand is also implicated in VLDL 
production (Das & Gursky, 2015; Jong et al., 1999; Shachter, 2001; Yao & Wang, 
2012; Kei et al., 2012). ApoC-III can also displace larger proteins like apoE from 
the surface of VLDL, and thereby prevent the clearance of apoB lipoproteins via 
receptors such as the LDL receptor (LDLr) that bind apoE (Sacks, 2015).  
The NMR structure of apoC-II in the presence of dodecyl phosphocholine 
micelles reveals a well-ordered helical conformation for the N-terminal half of the 
protein, with the exception of the first 12 residues, which are unstructured (Figure 
1.3, panel A) (MacRaild et al., 2004). The helices of apoC-II have distinct dynamic 
properties and are oriented in an open U-shaped conformation lacking long-range 
protein-protein contacts, but stabilized through interactions with the detergent 
micelle (MacRaild et al., 2004; Zdunek et al., 2003).  NMR structure of apoC-III on 
detergent micelles, which mimics its lipid-bound conformation, shows that the 
protein wraps around the micelle surface as a “necklace” of six, ~10 residue 
amphipathic helices, which are curved and connected via semi-flexible hinges 
(Figure 1.3, panel B) (Gangabadage et al., 2008). Overall, these structures show 








Figure 1.3 Molecular structures of apoC-II, apoC-III and apoE. Ribbon 
diagrams are colored from the N-terminus to the C-terminus (blue to red). 
(A) Human apoC-II in dodecyl phosphocholine (PDB ID: 1SOH) (MacRaild et al., 
2004) 
(B) The NMR structure of apoC-III was solved in complex with SDS micelles, 
mimicking apoC-III’s natural lipid-bound state (PDB ID: 2JQ3) (Gangabadage et 
al., 2008). 
(C)  The NMR structure of lipid-free full-length modified apoE (PDB ID: 2L7B) 
(Chen et al., 2011), with the C-terminal domain (yellow/red) wrapped around the 
N-terminal domain (blue). 
 
Activation of LPL by apoC-II is determined by the capacity of apoC-II to bind 
LPL and stabilize a ternary complex with the lipoprotein substrate by means of 
apoC-II lipid binding regions (MacRaild et al., 2004; Clarke & Holbrook, 1985). 
ApoC-II and LPL can form a complex free in solution or on the lipoprotein surface, 







1985). LpL activation by apoC-II is physiologically relevant because, as a surface 
constituent of VLDL and chylomicrons, apoC-II renders the TG core of these 
particles susceptible to enzymatic hydrolysis.  
ApoE is a major exchangeable apolipoprotein on VLDL and a minor protein 
of plasma HDL. ApoE plays a critical role in lipid transport, atherosclerosis and 
other metabolic diseases. It is a high-affinity ligand for LDLr and LDL receptor-
related protein (LRP), and also binds PG (PGs) (Weisgraber, 1994; Mahley, 1988; 
Mahley et al., 2009). ApoE is highly expressed in adipocytes during adipogenesis, 
and plays a key role in the regulation of adipose tissue and body fat mass (Kockx 
et al., 2018). Moreover, apoE is the major apolipoprotein that directs lipid transport 
in the brain, and apoE isoforms are important genetic factors pre-disposing to 
(apoE4) or protecting from it (apoE2) Alzheimer’s disease (Green et al., 2009; Wolf 
et al., 2013).  
ApoE can switch between a lipoprotein-bound and lipid-free state due to 
two independently folded structural domains, the N-terminal globular domain that 
forms a 4-helix bundle in solution, and the C-terminal domain that forms the 
primary lipid binding site (Hatters et al., 2006). The structure of the N-terminal 
domain, solved in 1994 by x-ray crystallography, was the first atomic-resolution 
structure of a human apolipoprotein (Dong et al., 1994). More recently, the 
structure of a full-length modified apoE was determined by NMR, providing more 
insight into domain-domain interactions that are important in lipid and receptor 






domain is loosely wrapped around the C-terminal domain, largely obscuring its 
receptor binding site. Upon binding to lipid, apoE adopts an active conformation 
wherein the N-terminal domain unfurls and exposes the C-terminal domain, 
including helix 4. This conformational change allows an array of basic residues in 
helix 4 to interact with acidic residues of LDLr and LDLr-related proteins (Chen et 
al., 2011; Mahley et al., 2009).  
Exchangeable apolipoproteins play major structural and functional roles in 
VLDL and importantly modulate VLDL metabolism. As described above, apoC-II 
activates LpL while apoC-III inhibits it and decelerates VLDL turnover, leading to 
formation of pro-atherogenic TG-rich VLDL; moreover, apoE accelerates VLDL 
clearance and maturation. Therefore, the rate and the products of VLDL 
metabolism depend on the balance between apoE, apoCs and LpL (Wang & Eckel, 
2009; Su & Peng, 2020). ApoE and LpL bind heparin and other 
glycosaminoglycans (GAGs), but the heparin binding of apoB is blocked on VLDL. 
These aspects are important for understanding the interactions of apoB-containing 
lipoproteins with GAGs, which are central to lipoprotein retention in the arteries 
and are explored in this dissertation. 
 
1.3.2 The non-exchangeable apolipoprotein, apoB 
1.3.2.1 Introduction to apoB and its domain structure 
ApoB is the major non-exchangeable apolipoprotein associated with LDL, 






particle, this protein is a marker for the number of these particles present in plasma. 
There are two major forms of apoB encoded by the same gene, full-length apoB, 
termed apoB-100 and a C-terminally truncated version corresponding to the N-
terminal 48% of apoB, termed apoB-48.  ApoB-100 is a glycosylated single-chain 
550 kDa protein containing 4,536 amino acids making it one of the largest proteins 
found in nature. (Bassendine et al., 2011; Hardman & Kane, 1986). ApoB-100 is 
synthesized in the liver and is essential for VLDL assembly and secretion.  ApoB-
48, a 241 kDa protein, consisting of 2152 residues, is synthesized in the intestine. 
This truncated version of apoB results from mRNA editing leading to early 
termination of translation. ApoB-48 is essential for assembly and secretion of 
chylomicrons (Mahley et al., 1984).  
The formation and secretion of VLDL is important for redistribution of energy in 
the form of lipids that protects the liver from excessive accumulation of TG and/or 
precursors of TG that may result in lipotoxicity and liver steatosis (Ginsberg & 
Fisher, 2009). ApoB-48 is required for transport of dietary lipids. Unlike apoB-100, 
apoB-48 lacks the LDL receptor binding site.  
Based on the amino acid sequence analysis, apoB-100 has been predicted to 
contain five major structural domains, including three amphipathic α-helical 
domains alternating with two amphipathic β-strand domains, arranged in the 
following order: NH2-α1-β1-α2-β2-α3-COOH (Segrest et al., 1994, Shelness & 
Sellers, 2001). ApoB possesses a globular N-terminal domain, which interacts with 






assembly (Dominiczak & Caslake, 2011). Mutation of apoB-100 at amino acid 
residue 3500 prevents its binding to LDLr and leads to a disorder known as familial 
defective apoB (Innerarity et al., 1990) resulting in hypercholesterolemia. The 
model for the apoB N-terminal domain is discussed in detail below. 
 
1.3.2. Model of the structure of N-terminal domain of apoB  
A molecular structure of apoB has not yet been determined. There are several 
reasons for this, but major reasons include its size, heavy glycosylation, and the 
fact it does not exist without lipid, which makes it difficult to crystalize. However, 
the N-terminal domain of apoB is homologous both to MTP and to lipovitellin. 
Therefore, these two proteins are considered as possible models of the structure 
of apoB. Lipovitellin, whose crystal structure was solved, is an ancient lipid-binding 
protein that transports lipids from the liver to the oocyte of egg-laying animals 
(Baker, 1988). MTP is a heterodimer composed of a large, 97 kDa subunit and 
protein disulfide isomerase.  Like apoB, MTP is essential for chylomicron and 
VLDL assembly and mutations in its genes lead to abetalipoproteinemia which is 
characterized by the inability to form apoB-containing lipoproteins, chylomicrons 
and VLDL (Gregg & Wetterau, 1994). The large subunit of MTP contains two 
amphipathic α-helical domains positioned at the entrance of the MTP-binding 
cavity, which mediates interaction with membrane vesicles and facilitates TG 
acquisition by nascent apoB (Shelness & Sellers, 2001; Read et al., 2000). The 






that perturb acyl chains in lipid bilayers, which may facilitate lipid extraction from 
membranes, and thus, lipid loading into a nascent apoB-containing particle (Read 
et al., 2000),  
The only currently available detailed model of apoB is that of its N-terminal 
domain, corresponding to the N-terminal 17% of apoB, apoB17. This model is 
based on the homology model of the related protein, lipovitellin (Figure 1.4) (Jiang 
et al., 2005; Meininger et al., 1984). Specifically, the α1 domain of the N-terminal 
domain of apoB and the N-terminal domain of the of the large subunit of MTP (~70 
kDa) are homologs of lipovitellin. The structural model proposed by several teams 
suggests that the N-terminal domain of apoB consists of a β-barrel domain, a 
helical domain, and a β-sheet domain (Figure 1.4) (Jiang et al., 2005; Segrest et 
al., 2001; Mann et al., 1999; Herscovitz et al., 2001). Lipovitellin and apoB are far 
from each other on the evolutionary tree, but nonetheless, the structural model has 
been validated by in-depth biochemical and biophysical experimental data (Jiang 
et al., 2005). Therefore, the lipovitellin-based homology model for apoB17 is widely 
accepted in the field. It gives insight into the N-terminal domain of apoB, which is 








 Figure 1.4 Three-dimensional homology model of apoB17 based on 
the x-ray crystal structure of lipovitellin (PDB ID 1LSH). Ribbon representation 
of the apoB17 model: blue for the β-barrel domain, red for the helical domain, and 
green for the C-sheet domain. Figure adapted from (Sali & Blundell, 1993; Jiang 
et al., 2005) 
 
1.4 VLDL assembly and secretion 
Both apoB and MTP are obligatory for VLDL and chylomicron assembly. Similar 
to other secretory proteins, apoB synthesis begins on the rough endoplasmic 
reticulum (RER). Because apoB is highly lipophilic, its proper folding and stability 
within the secretory pathway requires the addition of lipid co- and post-
translationally (Shelness & Sellers, 2001). Thus, its translocation to the ER lumen 
takes about 10 minutes and final formation of VLDL takes another 20 minutes for 
apoBto reach the cellular membrane before secretion due in part to modifications 






Overall, VLDL assembly and secretion was proposed to occur in 2 major steps 
involving apoB, MTP and lipids as described in (Figure 1.5). This 2-step model 
involves the binding of MTP to nascent apoB during ongoing translation while it is 
still associated with the ribosome. MTP plays multiple vital roles in VLDL assembly: 
i) it functions as a chaperone to stabilize apoB during early steps of translation in 
the rough ER, ii) it mediates transfer of lipids, phospholipids and TG to the growing 
chain of apoB, iii) it helps form the functional lipid-binding pocket in apoB and iv) it 
mediates the formation of protein-free-TG-rich lipid droplet in the smooth ER.  After 
the initial folding of apoB N-terminal domain concurrent with initial lipidation, MTP-
dependent lipid transfer converts the apoB/lipid intermediate into a core-containing 
emulsion particle concomitant with the ongoing translation of the first large 
amphipathic β-domain of apoB. (Shelness & Sellers, 2001; Gordon & Jamil, 2000; 










Figure 1.5 The VLDL maturation pathway. Figure adapted from (Shelness & 
Sellers, 2001). 
1. The lipovitellin-like lipid binding cavity in apoB N-terminal domain is formed 
while apoB is still attached to the ribosome as the translation is ongoing. 
2. This lipid binding cavity allows for interaction with MTP. This interaction results 
recruitment of phospholipid and TG to the growing particle.  
3. The interaction of apoB with MTP mediates lipid transfer, forming a neutral lipid 
core. 
4. Further addition of lipid creates a spherical emulsion-like particle. 
5. The particle is released from the ribosome into the rough ER lumen, then 
transported to the smooth ER where apoB-free TG-rich lipid droplet was formed 






6. The precursors fuse to form mature VLDL; this step may be mediated by one 
or more α-helical fusigenic peptides in apoB (step B). 
 
Once an apoB-lipid-poor particle is released into the rough ER lumen, it is 
transported to the smooth ER where it fuses with the lipid droplet to ultimately form 
a mature VLDL in the second step (Figure 1.5). This fusion allows for a major 
expansion of the lipoprotein particle core. Thus, apoB is different than lipovitellin 
and MTP since it has the capacity to sequester extensive amounts of lipid in the 
form of spherical emulsion particles, mediated by apoB’s α-helical and β-sheet 
domains (Shelness & Sellers, 2001). 
The size of early immature apoB-containing particles changes from 
approximately 25 nm- diameter to mature VLDL particles of 30-80 nm-diameter 
(Shelness & Sellers, 2001; Alexander et al., 1976). The TG acquisition is thought 
to occur by the fusion of apoB lipid-poor precursors with protein-free TG-rich 
droplets mediated by MTP in the smooth ER (Alexander et al., 1976). Figure 1.5 
demonstrates the proposed steps of apoB biosynthesis, interaction with MTP, and 
fusion with TG emulsion particles.   
Formation of TG-rich apoB-containing lipoproteins can also be mediated by N-
terminal truncated forms of apoB. Members in our department used C127 cells to 
study the relationship between apoB length and ability to form VLDL (Carraway et 
al., 2000). C127 cells were transfected to express C-terminally truncated forms of 






particles in terms of size, density and composition were characterized. When 
[3H]oleate labeled particles were immunoprecipitated with antibodies to apoB, 
results showed that as apoB increased in length, the number of TG molecules per 
apoB increased almost 16-fold, while the number of phospholipids only slightly 
increased. Other groups reported similar findings  using other cells; expression of 
carboxyl  terminus truncated forms of human apoB in rat hepatoma cells showed 
that the length of apoB has a major effect on the buoyant density of the secreted 
lipoproteins (Yao et al., 2001). 
 
1.4.1 Regulation of VLDL assembly and secretion 
VLDL secretion is dependent on folding and maturation of apoB. Unlike other 
secretory proteins, apoB, being a very large, water insoluble protein does not 
always achieve a secretion-competent form. This is due to the fact that it is subject 
to quality control monitoring that can lead to its targeting to degradation through 
the secretory pathway via multiple mechanisms.  
The rate and efficiency of apoB maturation resulting in VLDL secretion is 
dependent on several factors: i) functional MTP, ii) neutral lipids, TG and CE, 
availability iii) co- and post-translational modifications of apoB, iv) LDLr in the 
secretory pathway, v) polymorphism in the signal sequence of apoB, and vi) 








MTP is obligatory for mediating apoB folding and lipidation to form VLDL. 
Therefore, mutations in the 75kDa subunit of MTP completely block apoB lipidation 
resulting in abetalipoproteinemia, a disease characterized by inability to transport 
dietary lipids, for example vitamin E, leading to developmental disorders (Wetterau 
et al., 1992).  Using cultured cell models that do not express MTP or when MTP 
activity is inhibited, it was demonstrated that apoB was cotranslationally targeted 
to degradation in a proteasome-dependent mechanism (Davis, 1999; Liang et al., 
1998).  
 
1.4.1.2 Lipid availability 
VLDL assembly and secretion provides an important mechanism for the liver 
to export excess lipids to prevent liver steatosis and toxicity. Thus, both TG and 
CEs regulate VLDL assembly and determine the percentage of apoB that is 
assembled into secretion-competent lipoprotein particles versus that which is 
misfolded and targeted for pre-secretory degradation (Davis, 1999).  
A predominant pathway for biosynthesis of core lipids for VLDL involves acyl 
transfer to diacylglycerol by the enzyme acyl conenzyme A: diacylglycerol 
acyltransferase (DGAT), which catalyzes the final stage of TG synthesis. Although 
the source for TG for VLDL assembly is still unclear, the origin of the cholesteryl 
ester (CE) that is packaged into the core has been identified and involves two 
intracellular cholesterol-esterifying enzymes: acetyl-CoA acyltransferase (ACAT) 






and intestine in both mice and nonhuman primates (Lee et al., 2000). In ACAT2-
deficient mice, CEification activity in the liver and small intestine was reduced by 
over 90% (Buhman et al., 2000). Additionally, ACAT2-deficient mice displayed 
reduced intestinal cholesterol absorption and resistance to dietary induced 
hypercholesterolemia (Buhman et al., 2000). From these studies it is clear that 
ACAT2 is responsible for CE production for chylomicron assembly, and thus, 
hepatic VLDL assembly (Buhman et al., 2000). While this is true for hepatic CE 
formation in mice and nonhuman primates, other studies suggest that ACAT1 is 
the predominant enzyme for CEification in the adult human liver (Zhang et al., 
1999; Spady et al., 2000; Chang et al., 2000). 
Reduced lipid availability leads to underlipidated apoB that is unable to form 
mature-secretion-competent VLDL. Under these conditions, apoB is delivered to 
the proteasome via retrograde translocation from the ER lumen to the cytosol, 
likely coupled with multiubiquitination and proteasome-mediated proteolysis in the 
cytosol (Davidson & Shelness, 2000; Liao et al., 1998). 
 Another study showed that in HepG2 cells, the translation of apoB appears 
to stop just before the completion of the carboxyl terminus (Pariyarath et al., 2001). 
Translation-arrested forms of apoB can be targeted for proteasome-mediated 
turnover. Protease accessibility experiments using apoB expressed in HepG2 cells 
have shown that the bulk of apoB resides in the ER lumen, while the carboxyl-
terminus of the protein may be exposed to the cytosol before its degradation 






1.4.1.3 Regulation by LDLr 
VLDL regulation by the LDLr was proposed based on the observation that apoB 
production in hepatocytes from LDLr knockout mice was 3.5-fold higher than that 
from wild type hepatocytes (Twisk et al., 2000). Lower production rates in the wild-
type hepatocytes were due to both the reuptake of newly secreted VLDL by the 
LDLr and to presecretory degradation of newly synthesized apoB, a process that 
was insensitive to proteasome inhibitors (Twisk et al., 2000). It has been proposed 
that the mechanism involves the intracellular interaction of LDLr with nascent 
VLDL, via either apoB or apoE. This would target nascent VLDL for presecretory 
degradation by an unknown mechanism, but may explain the overproduction of 
VLDL in genetic LDLr deficiency states and reduced VLDL production observed 
when LDLr is upregulated by statins (Twisk et al., 2000).    
1.4.1.4 Signal sequence 
Polymorphisms in the signal sequence of apoB lead to changes in plasma lipids, 
which most likely arises from variable rates of translocation of apoB into the ER. 
(Sturley et al., 1994). 
 
1.4.1.5 Co- and post-translational modifications of apoB 
 ApoB is modified by N-glycosylation, disulfide bond formation, 
phosphorylation and palmitoylation. N-Glycosylation of apoB occurs both co- and 
post-translationally. before it is translocated out of the ER and is perhaps the most 






studies in Chinese hamster ovary cells or fibroblasts transfected to express 
truncated apoB forms show that neither MTP nor ongoing lipidation is required for 
the translocation of the N-terminal 50% of apoB, but glycosylation is (Huang and 
Shelness, 1999).  
ApoB is highly glycosylated, enzymatically and non-enzymatically, in the 
liver and within the plasma. The N-linked oligosaccharides at the N-terminus of 
human apoB100 are important for the assembly and secretion of VLDL (Vukmirica 
et al., 2002). ApoB has 19 potential N-glycosylation sites, of which 16 asparagine 
residues spaced along the whole sequence of apoB are found to be 
glycosylated (Yang et al., 1989).   
 
1.4.1.6 Phospholipase A2 and phospholipase D 
Cytosolic calcium-independent phospholipase A2 (iPLA2) has been shown 
to be a cofactor in the post-translational maturation of VLDL precursors, perhaps 
priming the membranes for an important step in VLDL production (Tran et al., 
2000). iPLA2 may also be required for the MTP-dependent trafficking of TG into 
the smooth ER lumen (Tran et al., 2000).  
ADP-ribosylation factor 1 (ARF)-1-mediated activation of phospholipase D 
may be essential for the metabolic channeling of phospholipid into VLDL TG 
production (Asp et al., 2000). 
 






Each VLDL particle contains one copy of apoB-100 and multiple copies of 
exchangeable apolipoproteins, mainly apoC-II, apoC-III, apoC-I, and apoE. During 
TG hydrolysis by LpL, the lipoprotein core shrinks and the excess surface material 
is released from the parent lipoprotein in the form of either lipid-poor protein such 
as apoCs, or small HDL-sized particles containing phospholipids and apoE 
(Weisgraber, 1994; Feingold & Grunfeld, 2018).  
The resulting IDL particles continue to be hydrolyzed by LpL, and ultimately 
form LDL particles.  Thus, LDL is a direct metabolic product of VLDL. LDL contains 
one copy of apoB-100 on its surface, which comprises >95% of the total LDL 
protein content by mass and predominantly CEs with some TGs in the core. 
 Plasma levels of LDL are determined by the rate of LDL production and 
clearance, the latter largely regulated by LDL receptors on the liver. Approximately 
70% of circulating LDL is cleared via hepatocyte LDLr-mediated endocytosis.  The 
remainder is taken up by extrahepatic tissues (Goldstein & Brown, 2009; Goldstein 
& Brown, 2015). Therefore, an increase in the number of hepatic LDL receptors 
increases LDL clearance, leading to a decrease in plasma LDL levels (Goldstein 
& Brown, 1987; Zhang et al., 2012). On the other hand, a decrease in hepatic LDL 
receptors will reduce LDL clearance leading to an increase in circulating plasma 







1.6 Structural models of LDL 
 There are a number of challenges to studying LDL structure. The molecular 
mass of apoB-containing lipoproteins, which is ~3,000 kDa for LDL, is prohibitively 
high for solution NMR. Additionally, obtaining a truly homogenous sample of apoB-
containing particles for structural studies poses a challenge. VLDL, LDL and 
chylomicrons are highly heterogeneous particles, differing in size, protein and lipid 
composition. Even LDL particles, which contain a single copy of apoB and are 
relatively homogeneous in size, differ in the levels of cholesterol and the presence 
of minor exchangeable apolipoproteins. However, several groups have 
circumvented these challenges and have gleaned useful information on apoB 
structure. 
A relatively homogeneous subfraction of plasma LDL has been crystallized; 
however, the crystals did not diffract beyond very low resolution (Johs et al., 2006).  
Previous studies using immuno-cryo electron microscopy provided a low-
resolution model for apoB on LDL (Liu & Atkinson, 2011; Kumar et al., 2011). The 
most striking feature is that apoB wraps around the particle, with the N- and C-
terminal domains in close proximity to each other (Chatterton et al., 1991). The 
surface area that is not covered by apoB contains lipids (Figure 1.6) (Aviram et al., 
1988; Sommer et al., 1992; Liu & Atkinson, 2011). Important binding sites for LDLr 
and several apoB antibodies were mapped on this model (Kumar et al., 2011). The 
22 Å resolution model by Liu & Atkinson (2011) shows that apoB encloses the LDL 






barrel-like structure (Figure 1.6). This protein structure can accommodate different 
numbers and types of lipid molecules, which explains how the protein can adjust 
to the changes in the particle curvature and biochemical composition that occur in 









Figure 1.6 Low-resolution map of apoB structure on LDL surface obtained 
by immuno-cryo-electron microscopy. The volume in gray represents the 
overall shape of the LDL particle, which is overlaid with the high-density regions 
(color-coded as described below). Different views of the overlaid structure are 
shown. Arrows point to the protrusion representing the N-terminal domain. ApoB 
high-density regions (in orange) wrap around the LDL particle like a belt (Liu & 
Atkinson, 2011). The regions colored in green contour the rims of the discoidal 
particle and form a circle on the two flat surfaces. These regions of high density 
are attributed to apoB, and the lower densities on the flat surfaces (in gray) are 
phospholipids. Figure adapted from (Liu and Atkinson, 2011).  
 
In summary, apoB is a massive yet dynamic protein. The basics are known about 






regions. The N-terminal domain structure and its function in the genesis of 
lipoprotein particles are fairly well-understood. The overall barrel-like shape of 
apoB on LDL has been established, but the model for apoB on VLDL is still lacking. 
A complete, high-resolution structure of apoB on either LDL or VLDL would be 
groundbreaking. In the meantime, there are alternative approaches to explore 
apoB structure-function relationship, including combined biochemical and 
biophysical methods such as those used in this dissertation.  
1.7 Lipoproteins and atherosclerosis 
Atherosclerosis is a disease characterized by the presence of 
atherosclerotic plaque in arterial blood vessels. A plaque is a buildup of fats and 
other substances in the arterial walls, which leads to a hard deposition (termed a 
plaque) which restricts blood flow to the heart and the rest of the body. 
Atherosclerotic plaques and restricted blood flow may result in blood clots, heart 
attack, stroke and peripheral vascular disease, which are all forms of 
cardiovascular disease. The development of an atherosclerotic plaque is the result 
of Chronic inflammation of the blood vessels and systemic inflammatory responses 
(Libby et al., 2002). Plaque rupture and disassociation from the arterial wall can 
cause occlusion of the artery by blood clot. Notably, cardiovascular disease 
remains the leading cause of death worldwide (Hansson & Hermansson, 2011). 
Increased levels of circulating LDL and VLDL are associated with 
cardiovascular disease and the development of atherosclerosis. When lipoproteins 






modified via oxidation, glycation or enzymatic hydrolysis. These factors contribute 
to the atherogenicity of lipoprotein particles. For example, small dense LDL, which 
are particularly pro-atherogenic, are more likely to cross the endothelial barrier and 
to be retained in the arterial intima (Camejo et al., 1998; Khalil et al., 2004). Such 
modified particles are readily taken up by macrophages. This can promote the 
development of foam cells, a pathogenic form of macrophages, leading to an 
inflammatory response and, ultimately, to the development of atherosclerotic 
plaques.  
According to the widely accepted “response to retention hypothesis” of 
atherosclerosis (Williams & Tabas; 1998) (Figure 1.7), the initial step in this 
pathogenic process is the binding of LDL to PG such as heparan sulfate PG 
(HSPGs) in the extracellular matrix of the arterial wall (Camejo et al., 1998; Skålen 
et al, 2002; Khalil et al., 2004; Borén and Williams, 2016). After this initial binding 
step, the particles undergo enzymatic modifications, which increase the likelihood 
of lipoprotein retention. These modifications include oxidation and hydrolysis of 
both the lipid and the protein, which leads to deleterious biochemical and structural 
changes in LDL. Such modified particles are prone to fusion, which further 
augments their retention and promotes their uptake by arterial macrophages. The 
ultimate result of this cascade is the formation of an atherosclerotic plaque 








Figure 1.7 Response-to-retention hypothesis. Schematic flow is shown 
according to Williams and Tabas (1998).  
 
1.8  Role of glycosaminoglycans in lipoprotein retention 
The first step in the response-to-retention hypothesis is the binding of LDL to 
proteoglycans (PG) in the extracellular matrix of the arterial wall. PG are proteins 
modified by GAG polysaccharides. GAGs are long-chain compounds made up of 
hundreds of repeating disaccharide units. One of the sugars in each disaccharide 
unit is a hexosamine (glucosamine or galactosamine). Many PG contain a core 






One GAG that is particularly relevant to atherosclerosis and diabetes is 
heparan sulfate (HS). LDL binding to HS or its highly sulfated mimic, heparin, has 
been studied for decades and much progress has been made in our understanding 
of its molecular basis. Still, the details of these interactions are incompletely 
understood. These interactions are driven by Coulombic attraction of sulfates and 
carboxylates from heparin sulfate proteoglycans (HSPG) to lysine- and arginine-
rich segments of apoB (Camejo et al., 1998; Skålen et al., 2002; Hiukka et al., 
2009) as well as minor LDL proteins, apoE, apoJ and apoC-III (Ji et al., 1997; de 
Silva et al., 1990; Olin-Lewis et al., 2002; Hiukka et al., 2009). Several HSPG-
binding residue segments in apoB have been identified, yet the details of the 
interactions are missing, in part, because structural studies of apoB have been 
limited to low resolution. Chapter 4 of this dissertations addresses aspects of LDL-
heparin interactions and their relevance to human disease such as atherosclerosis 
and diabetes. 
A note on heparan sulfate and heparin. As stated above, the study 
presented in Chapter 4 utilizes heparin as a mimetic of HS, here I clarify why the 
use of heparin is legitimate. HSPGs are composed of repeating 14 linked 
disaccharide units, in which one monosaccharide is an α-D-glucosamine residue 
and the other, a uronic acid (Meneghetti et al., 2015). There are a few other 
polysaccharide differences that result in slight changes in structure, for example 
the D-glucosamine residues are N-acetylated in HS, whereas in heparin they are 






(Figure 1.8 B), heparin is more sulfated, and hence, more charged than HS, which 
contains both highly sulfated domains and less sulfated domains (Gallagher & 
Walker, 1985; Casu, 1989; Rosenberg & Lam, 1979). Additionally, HS has a higher 
maximum average molecular weight (~50 kDa), i.e., forms longer polymer chains 







Figure 1.8 HSPG, heparan sulfate and heparin molecules. 
A. Schematic of HSPG, with long glycosaminoglycan chains attached to a protein 
core. 
B. Chemical structures of the major repeating disaccharide units of heparin and 
heparan sulfate (figure adapted from Olczyk et al., 2015). 
 
Differences in composition between disaccharide substitution pattern and 
domain structure lead to distinct glycosidic linkage geometry and iduronate 
conformational equilibria that make HS structurally distinct from heparin 
(Meneghetti et al., 2015). HS with heparin-like features is produced by various 
tissues (Dietrick et al., 1975; Lyon et al., 1994; Vongchan et al., 2005) and cell 






al., 2015), and heparin can be considered as a tissue-specific form of HS. In a 
comprehensive review of HS and heparin biosynthesis, structure and protein 
binding, Meneghetti et al. (2015) concluded that the binding and biological activity 
of HS and heparin do not depend on sequence and charge alone, but also on 
conformational differences (Meneghetti et al., 2015).   
 
1.9 Lipoproteins in diabetes 
  Diabetes mellitus is a disease in which the levels of circulating glucose are 
elevated, and measured by HbA1c (glycated hemoglobin type 1c). There are 2 
types, type 1 and type 2. Type 1 develops due to a destruction of the pancreatic 
β-cells that produce insulin, either by autoimmunity or by a virus. Insulin, which is 
an essential hormone for glucose homeostasis and energy balance. Among its 
many functions, it promotes transport of sugar into cells to provide energy, but 
without it, cells cannot get access to this energy. Type 2 diabetes is characterized 
by normal production of insulin, but cells adequate cellular responses such that 
cells and do not take up glucose due in part to deficiency or inactivity of the insulin 
receptor. Over time, untreated diabetes will result in heart disease, stroke, kidney 
damage, and nerve damage. Cardiovascular disease, particularly premature 
atherosclerosis, is the major cause of mortality in untreated type 1 and type 2 
diabetes mellitus (Seshasai et al., 2011; Aronson, 2008). 
Human clinical studies, animal models and cell-based studies have firmLy 






atherosclerosis, and several underlying mechanisms have been proposed 
(Aronson, 2008; Shah & Brownlee, 2016). Most of these mechanisms involve 
changes in LDL properties during diabetes, including increased glycation and 
oxidation of LDL, increased population of small dense TG-rich LDL, decreased 
affinity for the LDL receptor, and increased LDL uptake by arterial macrophages, 
all of which can potentially augment the development of atherosclerosis (Camejo 
et al., 1998; Khalil et al., 2004; Aronson, 2008). Non-fasting levels of plasma TG, 
which can vary in healthy subjects depending on the genetic and environmental 
factors, are elevated in diabetes, metabolic syndrome, obesity and dyslipidemia, 
and represent an independent causative risk factor for atherosclerosis (Sarwar et 
al., 2007; Talayero & Sacks, 2011; Nordestgarrd & Varbo, 2014; Toth, 2016). 
One of the most important mechanisms linking diabetes to premature 
atherosclerosis involves increased LDL retention by arterial HSPG, which may 
result from changes to both LDL and PG in diabetes (Camejo et al., 1998; Khalil 
et al., 2004; Tannock & King, 2008). Increased binding to arterial PG was observed 
in LDL from hyperglycemic patients with type 1 and type 2 diabetes mellitus 
(Edwards et al., 1999; Hagensen et al., 2019). Moreover, the binding was restored 
to normal levels upon successful treatment of hyperglycemia (Hagensen et al., 
2019). 
LDL glycation, which occurs in the healthy state, is elevated in diabetes. 
Oxidative stress is also a hallmark of diabetes and lipoprotein glycation in vivo is 






glycoxidation(Stirban et al., 2013; Soran & Durrington, 2011). Glycation occurs at 
specific sites in apoB and phospholipids, alters structural and functional properties 
of LDL, and enhances its proatherogenic potential through several mechanisms, 
including increased arterial retention (Aronson, 2008; Shah & Brownlee, 2016; 
Tannock & King, 2008; Edwards et al., 1999; Hagensen et al., 2019; Stirban et al., 
2014).  
Other factors associated with diabetes can also significantly influence 
lipoprotein metabolism. For example, plasma TG levelsare elevated in diabetes, 
which is expected to influence the biochemical and structural stability of plasma 
lipoproteins, particularly VLDL which are the major plasma carriers of TG. These 
effects of TG are addressed in Chapter 3 of this dissertation.  Furthermore, 
diabetes is associated with an increase in inflammatory cytokines that not only 
promote systemic inflammation but can also act upon lipoproteins and affect 
lipoprotein metabolism. For example, tumor necrosis factor α (TNFα) increases 
secretion of hepatic VLDL enriched in TG by stimulating hepatic de novo fatty acid 
synthesis and an increase in lipolysis (Feingold & Grunfeld, 1992). Other cytokines 
like interleukin (IL)-1, IL-6 and the family of interferons increase lipolysis and, 
ultimately, increase the serum lipoprotein levels (Feingold & Grunfeld, 1992).  
Together, the combined effects of increases in circulating glucose, 
inflammatory cytokines, oxidative factors and changes in circulating plasma 
enzymes can alter the plasma lipoproteins, making the studies of patient-derived 






patient-derived LDL and VLDL with in vitro modifications of these lipoproteins that 
mimic their modifications in diabetes.  
  
1.10 Goals of this dissertation 
The overall goal of this dissertation is to explore how major lipoprotein 
modifications associated with diabetes influence biochemical, structural and 
functional properties of human plasma VLDL and/or LDL. Chapter 3 explores how 
changes in TG levels influence structural remodeling of human plasma VLDL and 
LDL. Chapter 4 is focused on LDL interactions with heparin in normal and diabetic 
subjects, both treated (good glycemic control) and untreated (poor glycemic 




Chapter 2: Materials and Methods 
2.1 Lipoprotein preparation 
Lipoproteins were obtained from either single donors or pooled from several 
plasma donors. Single-donor human very low-density lipoproteins (VLDL) and low-
density lipoproteins (LDL) were isolated from plasma of anonymous healthy 
donors, which had been purchased from a blood bank, Research Blood 
Components LLC (Boston, USA), in full compliance with the Institutional Review 






containing plasma by KBr density gradient ultracentrifugation in the density ranges 
1.019-1.063 g/mL for LDL and 0.94–1.006 g/mL for VLDL. Each isolated 
lipoprotein fraction migrated as a single band on agarose gels. Lipoproteins were 
dialyzed against standard buffer (10 mM Na phosphate, pH 7.4) containing 0.25 
mM EDTA, degassed, and stored in the dark at 4 °C.  
Prior to each experiment, single donor and pooled samples were thawed. 
Lipoproteins were kept frozen immediately before use, and never re-frozen after 
initial thaw. Samples were used for further studies within 2-3 weeks during which 
no protein degradation was detected by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) and no changes in the lipoprotein electrophoretic 
mobility were seen on agarose gels. 
To compare human lipoproteins from healthy and diabetic subjects, three 
different batches of pooled plasma obtained from 20 subjects each were used. 
Plasma was collected by our collaborators at the Lipid Laboratory of Hospital de 
Sant Pau (Barcelona, Spain) with written informed consent by the patients and 
upon approval by the institutional ethics committee. The plasma for each group 
(Nl, Gc and Pc patients, described below) was pooled and the lipoproteins were 
isolated by density gradient ultracentrifugation in the collaborator’s laboratory. 
Protein and lipid composition of lipoproteins was determined at the collaborators’ 
laboratory. The results are shown in Table 2.1. Plasma was from the following 
subjects:  a) healthy normolipemic and normoglycemic volunteers (Nl, mean value 






diagnosed with type-2 diabetes mellitus (DM2) and presented a poorly controlled 
glycemic index (Pc, HbA1c ≥ 7.5%, <HbA1c> = 11.4 ± 1.7%), and c) patients with 
type-2 diabetes who,+ depending on their clinical situation, were subjected to 
hypoglycemic treatment (e.g. diet, exercise, metformin and/or insulin) to improve 
their glycemic control (good control, Gc, HbA1c<7.5, <HbA1c>= 6.4 ± 0.8%).  
In another series of studies, we used plasma lipoproteins with naturally 
occurring low and high levels of endogenous triacylglycerols (TG), which were 
isolated from single-donor plasma of two healthy volunteers. Low- and high-TG 
VLDL contained 0.89 and 1.32 mM/L TG, respectively, while low- and high-TG LDL 
contained 0.63 and 0.98 mM/L TG, respectively. The values were measured in 
technical triplicates with 2% error, using an enzymatic assay for lipid measurement 







LDL Ch  TG  PL  UC  CE  ApoB 
Batch 1 
Nl 40.9  6.8  26.5  11.3  29.6  25.8 
Gc 38.2  7.6  25.3  9.6  28.7  28.8 
Pc 38.6  7.5  25.7  10.1  28.5  28.2 
Batch 2 
Nl 38.1  7.0  26.9  9.1  29.0  28.0 
Gc 35.5  7.5  24.2  7.8  27.7  32.9 
Pc 38.2  7.9  21.1  9.3  28.9  32.8 
Batch 3 
Nl 36.9  6.6  32.7  10.4  26.5  23.8 
Gc 35.3  7.3  31.1  9.6  25.7  26.3 
Pc 35.4  7.3  30.4  9.4  26.0  26.8 
 
 
Table 2.1. Biochemical composition of LDL isolated from pooled plasma of healthy 
and diabetic patients with good (Gc) or poor glycemic control (Pc). CE (CE) values 
were obtained by subtracting unesterified cholesterol (UC) from total cholesterol 
(Ch). The results were expressed as percentage of LDL mass or as mol/mol of 
apoB. Individual lipids PL/TG/UC/TC were estimated by individual assays (details 








2.2 Protein and lipid determination  
CE, TG, and phospholipids were quantified using enzymatic assays as 
described in published protocols (Bergmeyer, 1985). Enzymatic assays quantify 
various lipids by breaking them down to their core components.  
For example, TG are hydrolyzed into glycerol and free fatty acids (FFA). 
Then an optically-active dye that changes its spectral properties upon binding the 
lipid breakdown products is used as a reporter, and its signal is measured by 
spectroscopy. FFA were measured using an enzymatic colorimetric assay 
(Enzymchrom™ free fatty acid kit). This enzymatic assay converts FFA to acyl-
CoA and then to H2O2.  H2O2 reacts with a dye to produce a pink product, which 
can be detected at 570 nm and is directly proportional to the FFA content. 
 Protein concentration was determined using a modified Lowry assay using 
bovine serum albumin as a standard (Markwell, 1978). All concentrations were 
measured in technical triplicates, meaning the same sample was tested thrice.     
Lipid composition of selected lipoproteins before and after thermal or 
chemical denaturation was assessed by thin-layer chromatography. The lipids 
were extracted by 2:1 chloroform: methanol, then dried under nitrogen (Folch, 
1957). Known amounts of dry lipids were analyzed using hexane:ether:acetic acid 
(70:30:1 volume ratio) to separate neutral lipids, or 
chloroform:methanol:water:acetic acid (65:25:4:1 volume ratio) to separate polar 







2.3 Circular dichroism spectroscopy 
 Circular dichroism (CD) is a type of absorption spectroscopy that is used to 
investigate structure and stability of macromolecules such as proteins, lipids, 
nucleic acids, and their complexes. The method measures differential absorption 
between the right and left circularly polarized light by chiral molecules. CD is a 
useful tool for structural studies of such chiral molecules and their complexes in 
solutions and in thin films. In our research, we record CD signal from specific 
protein and lipid moieties to monitor structural transitions in LDL and VLDL.  
 The information content in CD spectra depends upon the wavelength range. 
In far-UV CD range (wavelengths 180-250 nm), the CD signal of proteins results 
from the electronic transitions in the peptide group and depends upon the 
conformation of this group, i.e. on the protein secondary structure (Chou & 
Fasman, 1978). Since the helix is the ultimate chiral structure, far-UV CD signal is 
the strongest for an alpha-helix, although other secondary structural elements, 
such as the beta-sheet, beta-turn, or random coil, also have characteristic far-UV 
CD spectra (Figure 2.1). Therefore, measuring far-UV CD spectra enables one to 








 Figure 2.1 Far-UV CD spectra of model peptides representing basic 
secondary structural elements. The spectra for an α-helix (solid line), β-sheet 
(dots and dashes), β-turn (dashed line), and random coil (dotted line) are shown. 
Figure adapted from (Johnson, 1988).   
 
 Near-UV CD is usually recorded at 250-310 nm where the main 
contributions come from aromatic residues and disulfide bonds. This spectral 
range is generally used for assessing changes in tertiary structure of globular 
proteins (Fasman 2013, Chapter 4). However, for the large lipid-associated protein 
apoB, this approach is not suited since the CD signal at 250-300 nm does not 
change much even upon complete thermal denaturation of LDL or VLDL 








cooperative secondary structural unfolding is detected in apoB upon thermal 
denaturation of LDL or VLDL by far-UV CD (e.g. at 220 nm); therefore, far-UV CD 
is also unsuited for stability studies of these lipoproteins (Jayaraman et al., 2005).  
 Interestingly, studies from our laboratory have shown that the CD signal at 
longer wavelengths, circa 310-340 nm, changes dramatically and irreversibly upon 
lipoprotein denaturation, when a large negative peak centered circa 320-330 nm 
becomes apparent (Figure 2.3 panel A) (Jayaraman et al., 2005, Guha et al., 
2007). These wavelengths are outside the protein range and, therefore, this CD 
peak must come from lipids. Notably, this near-UV CD peak coincided with 
lipoprotein disruption observed by EM, and was attributed to changes in the 
packing of optically active lipids, such as carotenoids and CEs, upon their release 
from the lipoprotein core and coalescence into droplets (Jayaraman et al. 2005). 
Therefore, in our studies we use near-UV CD signal at 320 nm to monitor 
lipoprotein rupture and disintegration upon thermal denaturation and to assess 
how lipoprotein thermal stability is influenced by the biochemical changes in 
lipoproteins, e.g. change in TG content, oxidation and glycation in vitro and in vivo 
(Jayaraman et al., 2019). Simultaneously with near-UV CD, we also record 
turbidity (dynode voltage) as a complementary method to monitor lipoprotein 
denaturation (described in part 2.5 below).  
 In our studies, CD data were recorded by using an AVIV-400 
spectropolarimeter equipped with thermoelectric temperature controller. Far- and 






250 nm and 250-350 nm, respectively. To monitor thermal stability, the thermal 
denaturation data were recorded at a constant wavelength of 320 nm. Lipoprotein 
solutions containing ~0.1 mg/mL protein in standard buffer containing 150 mM 
NaCl were heated and cooled from 5 to 98 °C at a constant rate of 11 °C/h. Heat-
induced changes in near-UV CD were monitored at 320 nm to track lipoprotein 








Figure 2.2. Heat effects on the protein secondary structure of LDL. Figure 
adapted from (Jayaraman et al., 2005). The far-UV CD spectra (A) and the thermal 
denaturation curves (B) were recorded for LDL (40 µg/mL apoB) in standard buffer 
containing 150 mM NaCl. The denaturation data were recorded at 220 nm upon 
sample heating and cooling at a rate 11 K/h (▫) and 80 K/h (▪) (Jayaraman et al. 
2005). No cooperative (sigmoidal) unfolding of the secondary structure of apoB is 
observed by far-UV CD even upon heating to 98 °C when LDL is completely 
denatured, as seen by electron microscopy and large changes in turbidity. 










Figure 2.3 Thermal transition of VLDL measured by CD. (A) Near-UV CD 
spectra of intact and thermally-denatured VLDL. VLDL that have been thermally-
denatured by heating to 98 °C (black line) show a large negative peak at 320 nm, 
which is not observed in intact VLDL (grey). (B) Thermal denaturation data θ320 (T) 
recorded at 320 nm by CD at a scan rate of 80 °C/h (black) or 10 °C /h (gray). 
Double arrows indicate a shift in the heating curves that results from the difference 
in the scan rate. Figure adopted from (Guha et al., 2007).  
 
A note on concentration normalization in CD spectroscopy.  
CD signal is measured in millidegrees (mdeg) and is usually normalized for 







peptide group contributes to the signal) or molar ellipticity Θ (in near-UV, where 
each protein molecule contributes). This is done using the following expressions: 
 [θ] = θ*M0 / (10*L*C)   mean residue ellipticity (far-UV CD) 
  = θ*Mw / (10*L*C)  molar ellipticity (near-UV CD) 
 Here, θ is the measured CD signal in millidegrees, Mw is the molecular 
weight of the protein in Da, Mo is the mean residue weight (Mo = Mw/(N – 1), where 
N is the number of amino acids), L is cell pathlength in cm, and C is protein 
concentration in mg/mL.   
 In our lipoprotein studies, near-UV CD signal comes from lipids rather than 
the protein, so none of these conventional normalization protocols are applicable. 
Therefore, we normalized the signal per lipoprotein particle (i.e., per mole of apoB 
since each lipoprotein contains one apoB molecule), or report the raw CD data in 
millidegrees and specify the experimental conditions. For our studies, L=1 mm, C 
1-0.1 mg/mL protein, Mw= 550 kDa, Mo = 121 Da.  
 A note on Mw: In this study a value of 550 kDa was used for calculations. 
This Mw is that of the mature, glycosylated form of apoB. The protein moiety without 
the addition of sugars has a Mw of 513 kDa (Law et al., 1986).  
 
2.4 Turbidity analysis 
As a complementary method to assess lipoprotein stability, we monitored 
changes in turbidity during lipoprotein heating and cooling at 320 nm by using 






Benjwal et al., 2006). Dynode voltage is high voltage applied to the photomultiplier 
of the UV detector to compensate for the reduction in the light intensity that may 
result from light absorption and/or scattering by the sample. Similar to turbidity, 
dynode voltage will increase if the particle size increases, e.g., upon lipoprotein 
aggregation or fusion. Therefore, measuring dynode voltage in CD experiments 
enables one to monitor changes in the particle size resulting from the lipoprotein 
remodeling upon heating (Gursky et al., 2002,; Benjwal et al., 2006). Previous 
studies from our laboratory showed that such a remodeling involves lipoprotein 
fusion, followed by lipoprotein rupture and release of apolar core lipids that 
coalesce into droplets and subsequently aggregate (Gursky et al., 2002; 
Jayaraman et al., 2005; Guha et al., 2007; Lu et al., 2012). These morphological 
transitions cause an initial increase in turbidity due to increased particle size upon 
fusion, aggregation and droplet formation. This increase in turbidity can be 
followed by a drop in signal upon phase separation in aqueous suspensions of fully 
denatured lipoproteins (Jayaraman et al., 2019), which occurs at high 
temperatures. In our research, we used turbidity measurements to compare 
lipoprotein stability and determined how it is influenced by physiologically relevant 
variations in the lipoprotein composition (e.g. TG content).   
To correlate heat-induced structural changes from CD and turbidity analysis 
(monitored by dynode voltage), both types of data can be recorded simultaneously 
from the same sample at the same wavelength. Previous studies from our 






a large increase in the negative CD signal and in turbidity (Figure 2.4), indicating 
concomitant changes in the lipid packing and formation of larger particles and/or 
aggregates (Jayaraman et al., 2005; Guha et al., 2007). These changes showed 
a strong dependence on scan rate which is a hallmark of slow kinetically-controlled 
transition (Gursky et al., 2002), and shifted to lower temperatures at slower heating 
rates (gray and black lines in Figures 2.3 B and 2.4 B). In this dissertation, the 
relatively slow scan rate of 11 deg/hour was used to ensure that the transition is 
complete upon heating to 98° C, which is the highest temperature accessible in 








Figure 2.4.  Effects of scan rate on the near-UV CD and turbidity thermal 
denaturation curves of LDL. The CD (A) and dynode voltage (turbidity) data (B) 
were recorded simultaneously from the same LDL sample (3.3 mg/mL protein 
concentration) during heating and cooling at 80 K/h (fast, black line) and 11 K/h 
(slow, gray line) at 280 nm, which corresponds to the shoulder of the near-UV CD 
peak at 310-320 nm. Double arrows indicate shifts in the heating curves that result 
from the difference in the scan rate. In this dissertation, I used the slow scan rate 
of 11 K/h to ensure that the lipoprotein denaturation transition is complete in the 
temperature range accessible by CD spectroscopy (below 98 °C). Figure adopted 








2.5 Fluorescence spectroscopy 
Fluorescence spectroscopy is a powerful technique to study changes in the 
chemical composition and environment of optically active moieties (fluorophores) 
in macromolecules such as proteins, lipids and their complexes. Here, we used 
two types of steady-state fluorescence measurements. First, we measured 
intrinsic tryptophan fluorescence of LDL and VLDL. Tryptophan residues in lipid-
binding proteins are often located at the protein-lipid interface (Adamian et al. 
2011).  ApoB contains eight Trp residues (Cladaras et al. 1986). Optical properties 
of some of these tryptophans (e.g. emission intensity and peak wavelength) can 
change upon changes in local Trp environment resulting from altered protein-lipid 
and protein-protein interactions. Therefore, we used intrinsic Trp fluorescence to 
monitor the overall lipoprotein integrity. The spectra were recorded at 305-400 nm 
with excitation wavelength λex=295 nm, which corresponds to the absorption 
maximum of Trp, and 5 nm excitation and emission bandwidths.  
We also used fluorescence to monitor the extent of LDL glycation, which is 
a hallmark of diabetes (described in detail in Chapter 4). Advanced glycation end-
products (AGEs) are proteins, lipids or lipoproteins that have become glycated 
upon a non-enzymatic reaction resulting in a covalent binding of sugars. AGEs are 
a complex group of compounds that play a major role in the pathophysiology and 
progression of age-related diseases and diabetes (Vistoli et al., 2013). The AGEs 
are formed as a result of the “Maillard reaction”, which consists of several steps. 






group of an amino acid (e.g. Arg) or a protein (R-NH2)), forming a Schiff base, and 
with further structural modifications (oxidation, dehydration and degradation) the 
reaction yields stable AGE compounds, termed Amadori products (Stirban et al., 
2014). AGEs are divided into three groups depending on fluorescence and whether 
or not they promote protein crosslinking: fluorescent proteins that are crosslinked, 
non-fluorescent proteins that are crosslinked, and non-crosslinked proteins 
(Ahmed, 2005). There are several methods to detect AGEs, but this study utilized 
the intrinsic fluorescence of the compounds associated with the Amadori products. 
To this end, the emission of AGEs was monitored at 450 nm with λex=350 nm. The 
spectra were recorded at 25°C using Varian Cary Eclipse spectrofluorimeter.  
 
2.6 Transmission electron microscopy  
Samples were analyzed by electron microscopy (EM) to visualize 
lipoprotein particle size and morphology, using the negative staining technique. A 
4 μL aliquot of a lipoprotein sample containing 0.05-0.1 mg/mL protein was 
incubated for 1 min on a carbon, Formvar-coated 300 mesh copper grid. After 
blotting excess fluid, the sample was washed three times with standard buffer, and 
stained with 1% uranyl acetate, blotted, and air-dried. Lipoproteins were then 
image on a d by CM12 transmission electron microscope (Philips Electron Optics) 
at 25°C using a 50,000x magnification; images were recorded on a TVIPS TEM-







2.7 Gel electrophoresis  
Particle size distribution in lipoprotein samples was determined by non-
denaturing polyacrylamide gel electrophoresis (NDGE) (Lu et al., 2012; Lu et al., 
2013). Six μg protein samples were resolved on Novex™ 4–20% or 4% Tris-
glycine gels (Invitrogen) and gels run to termination at 1500 V-h under non-
denaturing conditions in Tris-glycine buffer (pH 8 – 8.5).  
Protein integrity, size, and possible fragmentation, were determined by SDS 
PAGE (Lu et al., 2012; Lu et al., 2013). The gels were loaded with samples 
containing 5 μg protein per lane and run at 200 V for 1 h under denaturing 
conditions (%SDS-Tris/glycine buffer pH 8-8.5). The gels were stained with 
Denville blue protein stain (Denville Scientific) to visualize protein bands. 
To assess the charge of the lipoprotein particles upon various protein and 
lipid modifications, samples were resolved on agarose gels using the TITAN 
lipoprotein gel electrophoresis system. Lipoprotein samples containing 4 μg 
protein were loaded on the pre-cast gels that were run in sodium barbital buffer pH 
8.6 at 60 V for 40 min, then  at 125 V for 7 min. The gels were dried at 70 °C for 
20 min, stained with 0.1% w/v Fat red 7B stain (Sigma) in 95% methanol, destained 
in 75% methanol, and dried at 70°C to visualize lipids. 
 
2.8 Western blotting and dot blot analysis 
Western blotting was used to identify apoB and its fragments in samples 






aliquots of VLDL or LDL solutions (0.5 - 1 mg/mL protein in standard buffer) were 
loaded on a Novex 4-20% gel and run at 200 V for 1 h under denaturing conditions 
as described above. The proteins were electro-transferred onto polyvinylidene 
fluoride membranes for 90 min at 100 V. The membranes were incubated with 
apoB (#ab27626, Abcam), apoE (#AB947, Millipore), apoJ or apoC-III (#sc-
166907 and #sc-293227, Santa Cruz) followed by incubation with horseradish 
peroxidase-conjugated secondary antibodies for visualization (#B-1215, Boston 
Bioproducts). In a separate series of experiments, the integrity of specific apoB 
regions was probed using monoclonal antibodies from the laboratory of Dr. Yves 
Marcel (University of Ottowa, Heart Institute). Primary antibodies used were Mb18 
(epitope 994-1082), Bsol7 (epitope 4517-4536) and 4F6 (epitope 3569-3925).  
Secondary antibody was goat-anti-mouse HRP (#B-1115, Boston Bioproducts). 
The signal was developed with Thermo Scientific™ SuperSignal™ West Femto 
Chemiluminescent Substrate (#PI34095, Fisher). Images were collected with 
KwikQuantimager. Exposures from 1 s to 4 min were used. 
Dot blot analysis was performed to assess oxidized phospholipids in intact 
and modified lipoproteins. For dot blot analysis, 5 μl of LDL (0.5 mg/mL protein in 
standard buffer) were applied on a nitrocellulose membrane (#09-301-109, Fisher) 
and dried overnight at ambient temperature to ensure reproducible results. The 
membranes were rinsed with distilled water and blocked in 5% w/v nonfat dry milk 
in Tris buffered saline pH 7.6 containing 1x Tween-20 (TBST) (#IBB-181, Boston 






overnight with primary antibodies, either E06 (for oxidized lipids) (#330001, Avanti 
Polar Lipids), or rabbit polyclonal anti-apoB (#ab27626, Abcam) in 5% nonfat dry 
milk in TBST). The blots were washed thrice in TBST and then incubated at 
ambient temperature for 1 h with HRP-conjugated secondary antibodies in TBST. 
The membranes were washed thrice with TBST. The membranes were then 
incubated with Chemiluminescent Substrate (Thermo Scientific™ SuperSignal™ 
West Femto #PI34095, Fisher). Bands were visualized using KwikQuant imager. 
Exposures from 1s to 4 min were collected.  The 30 s exposure was used in all 
figures. In all experiments, apoB was used as a loading control. The dot blot 
analysis was performed by Dr. Shobini Jayaraman. 
 
2.9 Size exclusion chromatography 
To determine particle size distribution in intact and modified lipoproteins and 
to assess lipoprotein aggregation, size exclusion chromatography (SEC) was 
utilized. SEC was performed using a Superdex 200 XK 16/100 column (GE Life 
Sciences), which is a relatively low-resolution preparation-grade column, to isolate 
fractions from mixtures with large differences in particle size (for example, samples 
containing mixtures of lipoproteins and free proteins). A Superose 6 10/300 GL 
column (GE Life Sciences), which is a high-resolution analytical-grade column, 
was used for separation and analysis of particles with smaller size difference. SEC 






system (GE Healthcare). Elution by phosphate buffered saline (10 mM Na 
phosphate, 150 mM NaCl, pH 7.5) was carried out at a flow rate of 0.5 mL/min. 
 
2.10 Heparin affinity chromatography 
We used heparin affinity chromatography as a tool to explore lipoprotein 
interactions with heparan sulfate PGs. For heparin affinity chromatography, 
HiTrap-HP column (#17040601, GE Life Sciences) was used. This pre-packed 
column contains heparin from porcine intestinal mucosa (Mw= 13.5-15 kDa) 
immobilized on sepharose. 
Prior to each experiment, the column (1 mL volume) was washed with 10 
column volumes of standard buffer. and was equilibrated with 5 volumes of 
standard buffer. LDL solution (0.5–0.8 mg protein) was filtered through a 0.2 
micron filter, loaded onto the column and allowed to interact with heparin for 10 
min. The flow-through fraction was eluted with 3 column volumes of standard 
buffer, and the bound fraction was eluted with 3 volumes of high-salt buffer (10 
mM sodium phosphate buffer, 1.0 M NaCl, pH 7.4). The peaks corresponding to 
these fractions are illustrated in Figure 2.5 showing a typical LDL profile. The peak 
fractions were collected, dialyzed against standard buffer, and used for further 
studies. Biochemical analysis of lipid and protein component (Table 2.2) showed 
no differences before and after heparin affinity column binding and release. All 






and oxidative LDL modifications, which were accelerated by heparin binding, as 







 Figure 2.5 Heparin affinity profile of LDL from a healthy single donor. 
LDL sample (0.5- 0.8 mg protein mg/mL protein in standard buffer) was loaded 
onto the HiTrap heparin Sepharose column and was eluted with a high-salt buffer 
as described in Section 2.11. Dotted line shows NaCl concentration (100% = 1 M 
NaCl). “Bound” denotes the peak corresponding to LDL that bound heparin; these 
LDL eluted in high salt. “Flow-through” denotes the peak corresponding to LDL 












LDL  TG  PL   UC  CE  Protein 
Intact  7.5  26.2  9.1  27.3  29.8 
Bound 6.6  25.1  8.2  27.1  32.9 
 
Table 2.2 Biochemical weight percent composition of single-donor normolipidemic 
plasma LDL before (Intact) and after isolation of the heparin-bound fraction 
(Bound). Bound LDL were isolated by heparin-sepharose affinity chromatography 
as shown in Figure 2.5. The LDL isolation and biochemical analyses were 
performed as described above in part 2.1. Four different LDL batches were used; 
the data for batch 1 are tabulated and presented here; the results for other LDL 
batches were similar. CE - CE; UC - unesterified cholesterol; PL - phospholipids; 
Protein - total protein. The values, which represent % of total weight, show the 
mean of three independent measurements with the accuracy of ±5%.  
 
2. 11 Lipoprotein oxidation  
Oxidation of lipoproteins by Cu2+ was carried out as previously described 
(Jayaraman et al., 2007). The advantage of this method compared to other 
methods of non-enzymatic (by H2O2 and NaOCl) or enzymatic oxidation (using 
myeloperoxidase) used in our and other laboratories (Jayaraman et al., 2007) is 






enables one to accurately assess small changes in the reaction rate and hence, in 
lipoprotein susceptibility to oxidation. In our studies, lipoprotein solutions (0.1 
mg/mL protein) were equilibrated at 37°C and the oxidation was initiated by adding 
CuSO4 to a final concentration of 5 μM. The reaction time course was monitored 
continuously by UV absorbance at 234 nm that reports mainly on the formation of 
conjugated dienes, which are the products of phospholipid oxidation (Pinchuk et 
al., 1998). Lipid oxidation at 37 °C was monitored using Varian Cary Biothermal 
denaturation-300 UV–Vis absorption spectrometer with thermoelectric 
temperature controller.  
 
2.12 Limited proteolysis  
Previous studies from our laboratory have shown that, in contrast to small 
exchangeable apolipoproteins, the large non-exchangeable apoB does not 
undergo cooperative structural unfolding even upon complete lipoprotein 
denaturation and disintegration (Jayaraman et al., 2005; Lu et al., 2012) (Figure 
2.2 panel B). As described above, this limits the utility of CD and fluorescence 
spectroscopy for studies of apoB conformation. However, current studies by Dr. 
Jayaraman showed that limited proteolysis provides a particularly sensitive tool for 
probing changes in apoB conformation and lipoprotein structure and stability 
resulting from various modifications. Therefore, we use this tool to probe for 






Limited proteolysis of apoB in LDL was carried out using trypsin (#T1426 
from Sigma), plasmin (#P1867 from Sigma), or matrix metalloproteinase 12 (MMP-
12) (#M9695, Sigma). These enzymes cleave the protein at different sites. Trypsin 
is a pancreatic protease that preferentially cleaves proteins at the carboxyl end of 
lysine or arginine residues. Plasmin is a plasma protease that preferentially 
cleaves at polar resides such as serine (Hedstrom, 2002). MMP-12 is a 
metalloprotease that selectively cleaves peptides at aliphatic, aromatic or proline 
residues (Eckhard et al., 2016). In our studies, LDL (0.5 mg/mL protein) was 
incubated either for 1 h with trypsin (200:1 substrate:enzyme wt/wt), or for 3 h with 
plasmin (40 mU/mL) or MMP-12 (10 U/mL) at 37 °C. The reactions were stopped 
by adding 1 mM phenylmethylsulfonyl fluoride (for plasmin and trypsin) or 50 mM 
EDTA (for MMP-12), and the reaction products were probed by SDS-PAGE.  
 
2.13 Reproducibility and statistical analysis 
All experiments were repeated three or more times to ensure reproducibility. 
Most studies of normolipidemic single-donor LDL were performed in triplicates 
using four different batches. Studies of pooled lipoproteins from plasma of 
normolipidemic and diabetic patients were performed in triplicates using three 
different LDL batches. All batches showed similar trends; the data for batch 1 are 









Chapter 3.  Effects of triacylglycerol on the structural remodeling of human 
plasma very low- and low-density lipoproteins  
3.1 Introduction, challenges, and strategies for sample selection and 
analysis 
Plasma TG levels are increased in diabetes, metabolic syndrome and 
dyslipidemia, and this increase may have adverse effects on lipoprotein structural 
stability, remodeling and functionality (Sarwar et al., 2007; Talayero & Sacks, 
2011; Nordestgaard & Varbo, 2014; Toth, 2016). VLDL is the major plasma carrier 
of TG, yet how the TG levels influence VLDL stability and susceptibility to structural 
and biochemical modification was not known. Previous studies from several teams 
including ours have shown that increased TG levels in human plasma HDL 
decreases particle stability and augments protein release from the lipoprotein 
surface (Sparks et al., 1995; Jayaraman et al., 2017). However, the effects of TG 
levels on VLDL and LDL stability have not been explored, in part, because the 
stability of these large heterogeneous lipid-loaded particles is difficult to study 
experimentally. Previous studies from our laboratory have overcome this difficulty 
and established an experimental approach for measuring VLDL stability by using 
thermal denaturation (Guha et al. 2007). This approach was later modified and 







I took advantage of this approach to determine how variations in the 
endogenous TG levels of human plasma VLDL and LDL influence their thermal 
stability and remodeling. (Jayaraman et al. 2019). Here I report a part of this study 
that addresses structural remodeling of VLDL and LDL with different levels of 
endogenous TG. To this end, I used two types of samples as described below.  
1) VLDL and LDL were isolated from normolipidemic single-donor plasma 
of healthy volunteer donors. The plasma was obtained from a local blood bank and 
lipoproteins were isolated by density gradient ultracentrifugation as described in 
Chapter 2. Two donors whose plasma were used had different levels of TG, but 
otherwise similar lipid composition (listed in Table 3.1 below). These two batches 
were termed high-TG and low-TG. The advantage of these samples was three-
fold: First, since only TG levels showed a difference while all other biochemical 
parameters were similar, they allowed us to clearly determine the effects of TG 
alone without the interference from other factors. Second, the availability of 
relatively large amounts of high-TG and low-TG samples obtained from healthy 
donors enabled us to perform an additional centrifugation step to prepare more 
homogeneous particles (at the same densities used for original isolation). This 
extra step helped avoid any potential interference from the variations in particle 
size on the data interpretation. Third, single-donor lipoprotein samples undergo 
minimal spontaneous modifications such as oxidation and hydrolysis and have 
longer shelf life, facilitating a detailed analysis of the effects of endogenous TG on 






2) I also used VLDL and LDL isolated from pooled plasma of diabetic and 
normolipidemic patients differing in their endogenous TG levels. These plasma 
lipoprotein samples were obtained from our collaborator, Dr. Jose Luis Sanchez-
Quesada (Cardiovascular Biochemistry Group, Research Institute of the Hospital 
de Sant Pau, Barcelona, Spain). TG levels in these samples were higher in diabetic 
patients, but it must be recognized that differences in other lipid and protein 
moieties could also contribute to the observed effects. For example, samples 
derived from diabetic patients such as those used in our study can be minimally 
modified via oxidation and hydrolysis (Sanchez-Quezada et al., 1996), and 
previous studies showed that oxidation of human LDL and VLDL affects their 
stability (Jayaraman et al., 2007; Guha et al., 2007). Furthermore, upon isolation 
and storage, lipoproteins isolated from patient-derived pooled plasma undergo 
gradual spontaneous oxidation and hydrolysis, which is initially small but becomes 
significant over time. These processes are beyond our control. To minimize their 
effects, we collected all biophysical and biochemical data within one week of 
sample thawing. Despite this, the results of these studies could be influenced by 
several factors including differences in the endogenous TG levels, as well as 
lipoprotein oxidation, hydrolysis and glycation (described in more details in Chapter 
4). We are aware of this issue and only compare the trends that are reproducible 







A major challenge in this dissertation research was the limited time to 
perform a wide array of biophysical and biochemical experiments on patient-
derived lipoprotein samples. We had to collect all data within the same short time 
frame for accurate data interpretation. For this reason, the workload was shared 
with Dr. Shobini Jayaraman who performed the biochemical analyses, while I 
analyzed the samples by EM and gel electrophoresis, unless otherwise stated. The 
final conclusions were derived from our collaborative effort.   
Controls used for our experiments included: (1) TG enrichment using triolein 
emulsions and (2) depletion of endogenous TG via enzymatic hydrolysis using 
lipoprotein lipase (LpL). In the first process, only TG levels were altered without 
changing any other lipid or protein constituents or causing any additional particle 
remodeling, as proven by biochemical analysis and western blotting. In the second 
process, additional controls were run to limit the action of LpL in TG hydrolysis. In 
fact, extensive lipoprotein hydrolysis by LpL is known to cause particle remodeling 
and affect phospholipids in addition to TG (Kwitervich 2000; Olivecorna et 
al.,1997). To avoid this remodeling in our experiments, a series of control 
experiments with different enzyme concentrations and incubation times was 
performed to identify a condition in which only TG was hydrolyzed without any 
other major biochemical or structural LDL modification. These and other control 
experiments were carried out by Dr. Jayaraman; they are reported in our paper but 
not in this dissertation. These controls enabled us to clearly establish the role of 






In Chapter 3, I report biophysical and biochemical analyses of human 
plasma VLDL and LDL differing in TG levels due to endogenous variations either 
in healthy subjects (part 3.2) or in diabetic patients (part 3.3). A brief description of 
a subset of other studies reported in our publication and the overall conclusions 
are provided in part 3.4.    
3.2 Analysis of single-donor VLDL and LDL from healthy subjects with 
differences in endogenous TG levels 
3.2.1 Characterization of high-TG and low-TG VLDL and LDL from healthy 
subjects 
Lipid composition of particles obtained from single-donor high-TG and low-
TG VLDL is depicted in Table 3.1. The results show slight differences in TG levels 
between high-TG and low-TG particles, while the differences in the levels of other 
lipids did not change.   
  The protein and particle integrity in high-TG, low-TG LDL and VLDL were 
assessed by SDS-PAGE and EM, respectively (Figure 3.1). For both lipoprotein 
classes, no substantial differences in the protein composition or the particle size 
of high-TG versus low-TG lipoproteins (Figure 3.1) were detected. Therefore, 
these lipoproteins provided a useful system to explore the effects of endogenous 








% PL UC CE TG Protein 
Low-TG VLDL 18.5 15.4 13 28.5 24.5 
High-TG VLDL 17.5 16.1 9 33 25 
      
Low-TG LDL 26 9 28 7 30 
High-TG LDL 24 7 29.3 12.4 27.3 
 
Table 3.1 Lipid composition of single-donor plasma VLDL and LDL with different 
TG content. Plasma VLDL and LDL were isolated by density gradient 
centrifugation, and lipids were extracted and analyzed by enzymatic assays as 
described in Chapter 2, section 2.2 and in (Bergmeyer 1985). CE - CE; UC - 
unesterified cholesterol; PL - phospholipids; Protein - total protein. Lipid 
composition is expressed as % of total weight. Values represent the mean of 
triplicate measurements, repeated three times to check reproducibility, with the 









Figure 3.1 Characterization of single-donor VLDL and LDL with differences 
in the endogenous TG levels. Lipoproteins isolated from plasma of one donor 
with high TG and another donor with low TG are marked “high-TG” (gray) and “low-
TG” (black). (A) SDS PAGE (4-20%, Denville blue protein stain) and (B) Negative-
stain transmission electron micrographs. Figure from (Jayaraman et al., 2019).  
 
3.2.2 Protein secondary structure and thermal stability of high-TG and low-
TG VLDL and LDL  
The protein secondary structure of high-TG and low-TG lipoproteins were 
compared using CD spectroscopy. Figures 3.2 panel A and 3.3 panel A show the 
far-UV CD spectra of VLDL and LDL, respectively. These spectra show a positive 







negative peak with minima at 208 nm and 222 nm characteristic of an α-helix. 
These minima are not very well defined and the positive peak at 193 nm is 
comparable in amplitude to that of the negative peaks, which indicates a 
combination of α-helix and β-sheet. This result is expected as apoB on LDL and 
VLDL contains a mixture of α-helical and β-sheet structure, while exchangeable 
apolipoproteins on VLDL are predominantly α-helical (Venyaminov & Yang, 1996; 
Kallenbach et al., 1996; Tilstra & Mattice, 1996). For each lipoprotein class, the 
low-TG and the high-TG lipoproteins do not show any major differences, indicating 
similar overall secondary structure (Figures 3.2 panel A and 3.3 panel A).  
Next, the lipoprotein stabilities were tested using thermal denaturation 
(Figures 3.2 panel B and 3.3 panel B). To record the thermal denaturation data of 
VLDL and LDL, the samples were heated and cooled at a rate of 11 °C/h, and 
changes in the particle size were monitored by turbidity at 320 nm. An increase in 
turbidity observed upon heating above 70–75 °C reflects irreversible lipoprotein 
fusion, rupture and coalescence into aggregated lipid droplets, while the sharp 
drop in turbidity upon further heating results from the phase separation in aqueous 
suspensions of denatured lipoproteins (for details see Chapter 2). 
        When heating VLDL (Figures 3.2 panel B) the transition midpoint was 
observed at lower temperatures in high-TG lipoproteins (gray lines), suggesting 
their increased susceptibility to remodeling as compared to their low-TG 
counterparts (black lines). A similar trend was observed in the heating data of high-






VLDL with a higher TG content undergo heat denaturation at lower temperatures 
and hence, are less thermostable than their low-TG counterparts.  Moreover, 
thermal denaturation transition in high-TG lipoproteins was much steeper, and 
hence, much more cooperative than that in low-TG lipoproteins (Figures 3.2 panel 
B and 3.3 panel B). Higher cooperativity suggests larger cooperative unit 
involvment in the transition of high-TG lipoproteins. A potential origin of this effect 
could be formation of larger particles upon thermal denaturation, fusion and rupture 
of high-TG lipoproteins.  Therefore, the next question we asked was how the 








Figure 3.2 Secondary structure and thermal stability of single-donor VLDL 
with high and low levels of endogenous TG. Far-UV CD spectra (A) and thermal 
denaturation data (B) of high-TG and low-TG VLDL. TG content in these 
lipoproteins is listed in Table 3.1. To record the thermal denaturationdata of VLDL 
(B), the samples were heated and cooled at a rate of 11 °C/h, and changes in the 
particle size were monitored by turbidity at 320 nm. Arrows in panel B show 










 Figure 3.3 Secondary structure and thermal stability of single-donor 
LDL with high and low levels of endogenous TG. Far-UV CD spectra (A) and 
thermal denaturation data (B) of high-TG and low-TG LDL. TG content in these 
lipoproteins is listed in Table 3.1. To record the thermal denaturation data of LDL, 
the samples were heated and cooled at a rate of 11 °C/h, and changes in the 
particle size were monitored by turbidity at 320 nm. Arrows in panel B show 
directions of temperature changes.  
 
3.2.3 Effects of endogenous TG levels on lipoprotein remodeling and fusion 
Previously, our laboratory showed that  thermal and chemical denaturation 
can be used to mimic aspects of VLDL and LDL remodeling in vivo, including VLDL 







et al., 2007, Mehta et al., 2003; Lu et al., 2012). Here, we utilize these methods to 
investigate how differences in the endogenous TG levels impact the remodeling of 
LDL and VLDL.  Low-TG and high-TG containing lipoproteins were incubated for 
10 min at 85 °C, cooled to 25 °C, and analyzed by SEC, NDGE and transmission 
EM.  
Native VLDL was eluted as a single peak in SEC (Fig. 3.4 panel A, dotted 
line), while heated VLDL showed an additional peak corresponding to smaller 
protein-containing species (Fig. 3.4 panel A, solid lines). Previous studies by Dr. 
Madhumita Guha from our laboratory showed that such smaller species released 
from VLDL upon heating comprise HDL-size particles and free proteins, mainly 
apoE and apoCs; this process mimics a release of the excess proteins and lipids 
from the surface of VLDL, which occurs during VLDL remodeling to form LDL 
(Guha et al., 2007). Importantly, our current results revealed that the release of 
such species was strongly TG-dependent: after heating, only high-TG VLDL 
showed a large SEC peak at 16–20 mL (gray line, Fig. 3.4 panel A) that 
corresponded to an additional band on the NDGE (Fig. 3.4 panel B). In contrast, 
the low-TG VLDL sample showed a single peak in SEC both before and after 
heating (Fig. 3.4 panel A) and a single band on the NDGE (Fig. 3.4 panel B). 
Hence, the results of SEC and native PAGE are in good agreement and clearly 
show more extensive thermal remodeling with protein release in high-TG versus 
low-TG VLDL. Samples used in these experiments were the same as those used 






This conclusion was further supported by lipoprotein visualization using EM. 
Electron micrographs of negatively-stained heated VLDL showed more extensive 
morphological changes and formation of larger particles in high-TG vis-a-vis low-
TG VLDL (Fig. 3.4 panel C).  
Together, these results convincingly show that, under otherwise identical 
conditions, high-TG VLDL undergo more extensive heat-induced structural 







Figure 3.4 The effects of endogenous TG levels on the lipoprotein 
remodeling and fusion of VLDL. VLDL from two single donors, one with 
endogenously high TG (gray) and another with low TG (black). The data for native 
low-TG VLDL (i.e., before heating) are shown as a control; these data fully 
superimposed similar data for high-TG VLDL. To compare the extent of thermal 
remodeling, the lipoproteins were incubated for 10 min at 85°C followed by cooling 
to 25 °C and analysis by SEC using Superose 6 10/300 GL column (A), 4% NDGE 
(B), and transmission electron microscopy (C) as described in Chapter 2. In panels 
A and B, exchangeable apolipoproteins released from VLDL are indicated by a 
square bracket; these proteins have been identified by mass spectrometry as apoE 
and apoCs (Jayaraman et al., 2019).  
 
 Similar to VLDL, high-TG LDL showed more extensive thermal remodeling 








a single peak circa 12 mL on SEC (Fig. 3.5 panel A, dotted line). Heated LDL 
showed additional peaks corresponding to larger particles (Fig. 3.5 panel A). Our 
current analysis using SEC and NDGE showed that in low-TG LDL, such fused 
and ruptured/aggregated particles were a minority, while in high-TG LDL the large 
aggregated particles became the majority (peak 3 in Fig. 3.5 panels A, B). Electron 
microscopy supported this observation: low-TG LDL showed little change in the 
particle size and morphology in these experiments, while high-TG LDL were 
extensively remodeled and coalesced into droplets and aggregates (Fig. 3.5 panel 
C).  Single-donor LDL with endogenous high and low TG  shown in these 









Figure 3.5 The effects of endogenous TG levels on remodeling and fusion of 
LDL. To compare the extent of thermal remodeling, the lipoproteins were 
incubated for 10 min at 85°C followed by cooling to 25°C and analysis by SEC 
using Superose 6 10/300 GL column (A), 4% non-denaturing PAGE (B) and 
transmission electron microscopy (C) as described in Chapter 2. Native (unheated) 
normolipidemic LDL were used as controls. In panels A and B, numbers mark 
native-size LDL (1), fused LDL (2), and ruptured/aggregated LDL (3).  
 
It is important to note that similar effects were observed in control studies 
when TG levels were altered artificially (either increased by adding exogenous TG 
upon incubation with triolein emulsions, or depleted enzymatically by LPL 








PAGE and EM clearly showed that lipoproteins containing higher TG levels 
underwent more extensive thermal remodeling, while those containing lower TG 
levels underwent minimal remodeling (Jayaraman et al., 2019). These control 
studies, taken together with our experiments using high-TG and low-TG LDL and 
VLDL (Figs. 3.2-3.5), clearly showed that the effects of variations in TG levels on 
the lipoprotein integrity and remodeling are similar regardless of the source of 
these variations, exogenous or endogenous. 
We conclude that, similar to VLDL with high TG levels, LDL with high TG 
levels undergo much more extensive heat-induced structural remodeling 
compared to their low-TG counterparts. This effect could potentially originate from 
two sources: the direct influence of core TG on the particle stability, aggregation 
and fusion, and an indirect effect due to increased generation of FFA upon TG 
hydrolysis at high temperatures. The latter effect was addressed in control 
experiments described below. 
 
3.2.4 Control studies to explore generation of FFA during thermal 
denaturation of normolipidemic LDL and VLDL  
FFA are potent lipid fusogens (Chung et al. 1995; Jayaraman et al., 2011). 
Phospholipid bilayers have a high affinity for FFA, and FFA easily penetrate the 
membrane bilayers by passive diffusion, which augments bilayer fusion, causing a 
disruption in the packing of the phospholipid monolayer (Chung et al., 1995). 






(Jayaraman et al., 2011). Previous studies from our laboratory showed that even 
a small (2-5%) increase in the lipoprotein content of FFA such as oleic acid leads 
to a greatly increased lipoprotein propensity to fuse and form lipid droplets 
(Jayaraman et al., 2011). Since TG are susceptible to hydrolysis with generation 
of di- and mono-acylglycerols and FFA (Mattson and Volpenhein, 1964), an 
increase in TG levels in the lipoprotein core may increase the likelihood of this 
process.  
To test this idea, Dr. Shobini Jayaraman investigated the FFA content in 
single-donor normolipidemic VLDL, LDL and HDL before and after thermal 
denaturation. The lipoproteins were either kept at 25 °C or were incubated for 30 
min at 90 °C followed by cooling to 25 °C. This leads to complete lipoprotein 
denaturation, fusion and rupture.  Agarose gel electrophoresis followed by lipid 
staining by fat red consistently showed that heated lipoproteins had higher net 
negative charge, suggesting an increased amount of FFA (Figure 3.6). 
Quantification of lipids as described in Chapter 2, section 2.2 showed a reduction 
in phosphatidylcholine and an increase in FFA content, which was consistent with 
higher net negative charge. Therefore, these FFA must be generated upon 
hydrolysis of lipoprotein lipids such as phospholipids and TG, which are particularly 







Figure 3.6 Agarose gel electrophoresis of VLDL, LDL and HDL (experiment 
performed by Dr. Shobini Jayaraman). Single donor normolipidemic lipoproteins 
that were either native or have been incubated for 30 min at 90°C (which leads to 
complete lipoprotein denaturation, fusion and rupture) followed by cooling to 25°C, 
were run through agarose gels. The gels were stained with fat red lipid stain.  
 
 These results revealed that thermal denaturation of VLDL and LDL is 
accompanied by lipolysis and generation of FFA. Similarly, lipid analysis of 
chemically- denatured lipoproteins (upon incubation with guanidine hydrochloride 
at 37°C) revealed an increased amount of FFA (Jayaraman et al., 2019). Together, 
these studies strongly suggested that when lipoproteins lose their structural 
integrity upon thermal or chemical denaturation, there is an increased solvent 
exposure of lipids, especially core TG, promoting their lipolysis. Therefore, lipolysis 
should be taken into account in the interpretation of thermal and chemical 








We conclude that increased propensity to thermal remodeling and fusion 
observed in high-TG VLDL and LDL compared to their low-TG counterparts can 
result, in part, from the indirect effect of higher FFA levels generated upon thermal 
denaturation. Such FFA were probably generated upon TG hydrolysis in denatured 
lipoproteins. Moreover, increased generation of FFA upon denaturation of high-TG 
lipoproteins helps explain the increased cooperativity in their thermal denaturation 
observed by turbidity (Figure 3.2). This increased cooperativity (evident from the 
steeper heating curves) reflects formation of larger particles in thermally- 
denatured high-TG proteins, which were observed by EM (Figures 3.4, 3.5). Such 
large particles are products of lipoprotein fusion and coalescence into droplets, 
and these processes are enhanced when FFA levels are elevated. 
 
3.3 Characterization of VLDL and LDL from pooled plasma of normolipidemic 
and diabetic patients 
3.3.1 Biochemical composition of VLDL and LDL from pooled plasma of 
normolipidemic and diabetic patients 
Elevated endogenous TG levels in plasma are a hallmark of diabetes 
mellitus. To test whether structural stability of lipoproteins is decreased in diabetes 
mellitus, I explored VLDL and LDL isolated from pooled plasma of  and healthy 
subjects. Concurrently, similar studies on HDL particles from diabetic patients were 
conducted by Drs. Jayaraman and Baveghems; our combined results were 






Another important hallmark of diabetes is increased glycation of plasma 
proteins, which results from increased plasma levels of glucose. Apolipoprotein 
glycation can affect the protein and lipoprotein structure and stability (Edwards 
1999). Plasma protein glycation is usually monitored by the glycemic index of 
hemoglobin, Hba1c. This index increases in diabetes but decreases upon 
glycaemic treatment of diabetic patients such as diet, exercise and metformin 
(Sanchez-Quezada et al. 1996), thus providing a useful diagnostic biomarker and 
a treatment readout for diabetes.   
In our studies, the patients were divided into three cohorts on the basis of 
their medical history and HbA1c: 1) healthy subjects; mean HbA1c of 5.2 ± 0.2% 
(normolipidemic, Nl), 2) diabetic patients; mean HbA1c of 6.4 ± 0.8% with good 
glycemic control due to treatment (good control, Gc), and 3) newly-diagnosed and 
untreated diabetic patients mean HbA1c of 11.4 ± 1.7% (poor glycemic control, Pc) 
(see Chapter 2, section 2.1 for details). Plasma from each cohort was pooled and 
the lipoproteins were isolated and analyzed for biochemical composition, structure 
and stability. 
Table 3.2 lists the lipid and protein composition of VLDL and LDL from these 
three cohorts. Lipoproteins isolated from two independent batches of pooled 
plasma were explored in this dissertation. The results for both batches are shown 
in Table 3.2.  The trends observed in lipoproteins from batches 1 and 2 were 
similar. SDS-PAGE and transmission electron microscopy analysis detected no 























Gc 20.9 49.0 20.0 9.2 11.7 10.0 





















Gc 38.2 7.6 25.3 9.6 28.7 28.8 
Pc 38.6 7.5 25.7 10.1 28.5 28.2 
Batch 2 
VLDL 
Nl 24.0 39.0 24.1 8.1 15.8 12.9 
Gc 21.9 43.8 21.4 7.7 14.2 12.9 





















Gc 35.5 7.5 24.2 7.8 27.7 32.9 
Pc 38.2 7.9 21.1 9.3 28.9 32.8 
Table 3.2 Biochemical composition of lipoproteins obtained from pooled plasma of 
healthy and diabetic patients. Lipoproteins from normolipidemic (Nl) diabetic 
subjects with good glycemic control (Gc) or poor glycemic control (Pc) were 
pooled, and lipid composition of these particles was determined (see Chapter 2, 
part 2.2 for details). PL - phospholipids; TG – triacylglycerol; UC - unesterified 
cholesterol; CE - CE; Ch – total cholesterol (UC+CE); Protein - total protein for 
VLDL, and per mol of apoB for LDL. The values are shown as % of total weight 






3.3.2 Secondary structure and thermal stability of VLDL and LDL from 
healthy and diabetic patients. 
  Secondary structural and stability studies of pooled VLDL and LDL revealed 
clear cohort-specific differences (Fig. 3.7). Far-UV CD spectra of VLDL showed 
less well-ordered secondary structure in VLDL of diabetic patients (Fig. 3.7 panel 
A), with the most ordered structure observed in Nl VLDL (black) and least order in 
Pc VLDL (gray). Importantly, studies of VLDL structural stability monitored by 
turbidity for changes in the particle size and by CD at 220 nm for secondary 
structural unfolding upon heating showed a rank order of stability Nl > Gc > Pc.  
Fig. 3.7  panel B shows representative CD thermal unfolding data of VLDL clearly 
illustrating this trend. 
A similar rank order was observed in the structure and stability of LDL, 
which was monitored by far-UV CD and turbidity (Fig. 3.7 panel C). Thus, Nl 
lipoproteins consistently showed more well-ordered protein structure and highest 
thermal stability, while Pc lipoproteins were least ordered and least stable (Fig. 
3.7).  
In summary, our results consistently showed that the structural stability of 
VLDL and LDL as well as their ordered secondary structure declines in order Nl > 
Gc > Pc (Fig. 3.7). This rank order was inverse of the cohort-dependent differences 
in the levels of endogenous TG in VLDL and LDL, Nl < Gc < Pc (Table 3.1).  These 
results suggest that structural stability of VLDL and LDL is related inversely to the 






glycation, oxidation and hydrolysis, which are enhanced in diabetes, may also 
contribute to the observed destabilization of LDL and VLDL in diabetes. These 
factors are described in detail in our publication (Jayaraman et al., 2019) and are 









Figure 3.7 Secondary structure and thermal stability of VLDL and LDL from 
healthy and diabetic subjects. Lipoproteins were isolated from pooled plasma of 
normolipidemic subjects (Nl, black) and of diabetic patients with either good 
glycemic control (Gc, light gray), or poor glycemic control (Pc, dark gray). VLDL 
(top panels), far-UV CD spectra (A) and CD thermal denaturation data at 220 nm 
(B). The thermal denaturation data monitor changes in the protein secondary 







and thermal denaturation data recorded by turbidity at 320 nm (D). The turbidity 
data monitor changes in the particle size during thermal remodeling. Arrows in 
panels B and D show the directions of temperature changes.  
 
3.3.3 HDL stability following manipulation of TG content 
The results of our studies of LDL and VLDL from diabetic patients were 
compared with similar HDL studies. In contrast to LDL and VLDL, differences in 
the TG levels of HDL in Nl, Gc and Pc patients were too small to cause any 
significant differences in the stability of  HDL derived from diabetic patients 
(Jayaraman et al., 2019). However, previous studies of HDL that were either 
artificially enriched with TG or depleted of TG were consistent with our current 
analysis of LDL and VLDL: the higher the TG content, the lower the structural 
stability of the lipoprotein (Jayaraman et al., 2017). We conclude that this trend is 
a general property of all major classes of plasma lipoproteins. It results, in part, 
from higher amounts of FFA generated during the denaturation of the TG-rich 
lipoproteins, as well as from their increased susceptibility to hydrolysis and 
oxidation demonstrated in control experiments by Dr. Jayaraman (Jayaraman et 
al., 2019). Other factors that can potentially contribute to the decreased stability of 
high-TG lipoproteins, especially in diabetic patients, include apolipoprotein 







3.3.4 Limited proteolysis of Nl, Gc, and Pc LDL  
In this series of experiments, we further explored conformational changes 
in apoB in Nl, Gc and Pc LDL, which could potentially contribute to the observed 
differences in their structural stability. Proteolytic enzymes are used as tools to 
investigate the susceptibility of apoB and other apolipoproteins to proteolysis to 
assess conformational changes in these proteins. 
First, we probed apoB conformation using limited proteolysis by trypsin, a 
pancreatic protease that preferentially cleaves proteins at the carboxyl terminus of 
lysine or arginine residues (Hedstrom 2002). In these series of experiments, LDL 
samples were incubated with trypsin for 1 h at 37°C, and the reaction was stopped 
by adding 1 mM phenylmethylsulfonyl fluoride (for details see Chapter 2, section 
2.13). Analysis by SDS-PAGE revealed that trypsin caused extensive apoB 
fragmentation in Pc-LDL, while in Nl-LDL and Gc-LDL apoB remained intact 
(Figure 3.8). These findings indicate that apoB on Pc-LDL underwent 
conformational changes that decreased its protection from proteolysis.  
MMP-12 and plasmin are proteolytic enzymes that function in the plasma 
MMP-12 is a metalloprotease that selectively cleaves peptides at aliphatic, 
aromatic or proline residues (Eckhard et al. 2016). Plasmin is a protease that 
preferentially cleaves at polar resides such as serine (Hedstrom 2002). MMP-12 
and plasmin were used to further probe for conformational changes in apoB in 
particles derived from diabetic patients (Figure 3.9). Similar to trypsin, both MMP-






while Nl-LDL and Gc-LDL remained intact. Therefore, the results seen in Figure 
3.8 are not limited to trypsin, but apply to other proteases regardless of their nature 
and preferred cleavage sites (Figure 3.9).  
Together, Figures 3.7-3.9 show that the apoB structure is less well-ordered 
in Pc-LDL as compared to Gc-LDL and Nl-LDL. This conclusion is strongly 
supported by far-UV CD spectra showing that the well-ordered secondary structure 
in apoB decreased in Pc-LDL but was partially restored in Gc-LDL (Fig. 3.7, panels 
A and C).  
Decreased ordering in apoB secondary structure likely stems from 
increased apoB glycation and oxidation in Pc-LDL. Increased oxidation and 
glycation are hallmarks of type-2 diabetes. Control experiments by Dr. Jayaraman 
revealed that: 1) mild oxidation and glycation of LDL leads to a decrease in the 
ordered structure in apoB and its structural stability, and 2) TG-rich LDL are more 
susceptible to oxidation and glycation (Jayaraman et al., 2019). Taken together, 
our results suggest that various factors contribute to decreased structural stability 
of LDL, which include biochemical and structural changes in both the protein (e.g. 
apoB glycation, oxidation and partial loss of secondary structure) and the lipid (e.g. 
increased TG lipolysis and generation of FFA). 
Unlike LDL, whose major protein is apoB that represents over 95% of the 
total protein content, VLDL contains not only apoB but also multiple copies of 
exchangeable proteins, mainly apoE and apoCs. Moreover, VLDL are much more 






heterogeneity complicates the interpretation of the limited proteolysis studies. 
Therefore, limited proteolysis studies in this dissertation have been performed for 







Figure 3.8 SDS PAGE (10-20%) of Nl-LDL, Gc-LDL and Pc-LDL before (native) 
or after incubation with trypsin for 1 hour at 37°C. St – molecular weight 
standards (in kDa), experiment run by Dr. Shobini Jayaraman. Gel was stained 











Figure 3.9 SDS-PAGE (10-20%) of Nl-LDL, Gc-LDL and Pc-LDL before (native) 
or after incubation for 3 h with plasmin (left panel) or MMP-12 (right panel). 
This experiment was performed by Dr. Shobini Jayarman. Details are described in 
part 2.13 of Chapter 2 and in Jayaraman et al. (2019). Gel was stained with 
Denville blue protein stain.  
 
3.4 Conclusions 
3.4.1 Increased TG levels in all major classes of plasma lipoproteins reduce 
lipoprotein stability  
 Our results show that increased TG levels destabilize VLDL and LDL and 
promoted their remodeling, including fusion, rupture and aggregation (Figures 3.1-
3.7). These effects were observed in single-donor VLDL and LDL from healthy 








well as in pooled VLDL and LDL from normolipidemic and diabetic subjects (Fig. 
3.7), and also in single-donor plasma VLDL and LDL from healthy subjects 
enriched with exogenous triolein [the latter experiments performed by Dr. 
Jayaraman and reported in (Jayaraman et al., 2019)]. Collectively, these findings 
reveal that variations in TG levels significantly influenced structural stability and 
thermal remodeling of VLDL and LDL: the higher the TG levels, the less stable 
were the lipoproteins and the more extensive was their remodeling. 
 A similar trend was observed in prior studies of HDL differing in their TG 
content. These studies showed that an increase in TG content in the core of 
plasma or reconstituted HDL destabilize the lipoprotein assembly, making it more 
labile to various perturbations (oxidation, thermal and chemical denaturation and 
enzymatic hydrolysis), and promotes apoA-I release in a lipid-poor/lipid-free 
aggregation-prone form (Jayaraman et al., 2017). Consequently, the destabilizing 
effects of TG are not limited to a particular apolipoprotein or lipoprotein class and 
may (in VLDL and HDL) or may not (in LDL) involve a substantial protein release 
from lipoproteins. Rather, these TG effects represent a common property of 








3.4.2 Mechanisms underlying decreased stability of TG-enriched 
lipoproteins 
We showed that TG have a direct destabilizing effect on lipoprotein particles 
as evident from the more extensive enzyme-induced digestion of TG-rich LDL 
(Figs. 3.8 and 3.9) and HDL (Jayaraman et al., 2019).  
Additional destabilization stems from indirect effects of TG via the 
generation of FFA. In fact, Dr. Jayaraman showed that lipoprotein disintegration 
during denaturation is accompanied by spontaneous lipolysis and generation of 
FFA, as illustrated in Figure 3.6 and described in part 3.2.3 and in (Jayaraman et 
al. 2019). Our results show that increased TG content leads to increased 
cooperativity of the lipoprotein disintegration during thermal remodeling (gray and 
black lines in Figs. 3.2 and 3.3). This transition involves lipoprotein fusion, rupture 
and coalescence into droplets. Therefore, its increased cooperativity suggests that 
in TG-rich lipoproteins a greater number of particles coalesce together, forming 
larger particles. This idea is strongly supported by SEC, non-denaturing PAGE and 
EM data of VLDL and LDL: high-TG lipoproteins not only undergo more extensive 
thermal remodeling but also coalesce into larger particles compared to their low-
TG counterparts (Fig. 3.4).These results are consistent with the effects of FFA on 
the remodeling of plasma HDL, LDL and VLDL reported previously from the Gursky 
laboratory: an increase in the FFA content greatly enhanced the cooperativity of 
the lipoprotein fusion and rupture, leading to formation of larger-sized particles, 






Therefore, increased cooperativity of thermal denaturation observed in TG-rich 
VLDL and LDL (gray lines in Figs. 3.2 B and 3.3 B) results, in part, from higher 
amounts of FFA generated upon disintegration of these lipoproteins. Additional 
destabilization comes from increased susceptibility of TG-rich lipoproteins to 
hydrolysis and oxidation demonstrated in control experiments by Dr. Jayaraman 
(Jayaraman et al. 2019). The FFA produced in these reactions augments 
lipoprotein destabilization and fusion. 
  In diabetic patients, additional factors contributing to lipoprotein 
destabilization probably result from changes in the apolipoprotein conformation. 
We observed such changes in LDL: limited proteolysis showed that apoB is less 
well ordered in Pc-LDL, and far-UV CD spectra supported this finding and showed 
that the structural ordering in apoB declined in order Nl>Gc>Pc (Figs. 3.7-3.9). 
These changes could result from the direct destabilizing effects of core TG on the 
protein conformation on LDL surface, as well as from biochemical modifications of 
apoB in diabetes such as oxidation and glycation (Aronson 2008; Shah & 
Brownlee, 2016; Edwards et al., 1999). Notably, TG-rich lipoproteins are more 
susceptible to such modifications (Jayaraman et al., 2019). 
 
3.4.3 Causal links between elevated TG levels in plasma lipoproteins and 
atherosclerosis 
Our in vitro findings are relevant to the lipoprotein remodeling and fusion in 






(Williams & Tabas, 1995; Boren & Williams, 2016), fusion of LDL and VLDL 
promotes lipoprotein retention in the arterial wall matrix and is an early triggering 
event in atherogenesis (Lu et al., 2012; Pentikäinen, M. O., 2000; Öörni, K.,2018). 
The results reported here suggest that increased levels of plasma TG, which are 
a hallmark of diabetes, metabolic syndrome, obesity and dyslipidemia and an 
independent risk factor for atherosclerosis (Öörni, K.,2018, Sawar et al., 2007; 
Talayero et al., 2011; Nordestgarrd et al., 2014 and references therein), promote 
pro-atherogenic lipoprotein oxidation and fusion. Likewise, in vitro studies by Dr. 
Jayaraman showed that, compared to TG-poor lipoproteins, TG-rich lipoproteins 
are more susceptible not only to structural remodeling but also to biochemical 
modifications such as oxidation and hydrolysis, which are pro-atherogenic 
(Jayaraman et al., 2019).   
Collectively, these findings suggest an additional causative link between 
elevated levels of plasma TG in various pathologic conditions and an increased 
risk of atherosclerosis, and help explain why elevated plasma TG is an 
independent risk of atherosclerosis. 
 
Chapter 4. Binding to heparin triggers deleterious structural and biochemical 








4.1 Introduction  
4.1.1 Possible mechanistic links between cardiovascular disease and 
diabetes 
 Cardiovascular disease, particularly premature atherosclerosis, is the major 
cause of mortality in type-1 and type-2 diabetes mellitus (DM2) (Seshasai et al., 
2011; Aronson 2008). Clinical, animal models and cell-based studies have firmLy 
established a causal link between diabetes and an increased risk of 
atherosclerosis, and several underlying mechanisms have been proposed 
(Aronson, 2008; Shah and Brownlee, 2016). Most of these mechanisms involve 
changes in LDL properties during diabetes, including increased glycation and 
oxidation of LDL, increased population of small dense TG-rich LDL, decreased 
affinity for LDL receptor, and increased LDL uptake by arterial macrophages, all of 
which can potentially augment the development of atherosclerosis (Camejo et al., 
1998; Khalil et al., 2004; Aronson, 2008).  
One of the most important mechanisms linking diabetes to premature 
atherosclerosis involves increased LDL retention by arterial HSPG, which may 
result from changes in both LDL and PG in diabetes (Camejo et al., 1998; Khalil et 
al., 2004; Shah and Brownlee, 2016). Increased binding to arterial PG was 
observed in both in vitro and in vivo studies of LDL derived from hyperglycemic 
patients with type-1 and DM2, and was attributed to increased glycation of apoB 






Another potential link between diabetes and atherosclerosis may result from 
the changes in the type and expression levels of arterial PGs (including HSPG) 
that occur in diabetes prior to atherosclerotic plaque deposition (Edwards et al., 
1999). However, the regulation of PG core protein expression and GAG chain 
synthesis are complex and poorly understood (Tannock and King, 2008). In this 
study, we use heparin as a model for HSPG to explore the interactions between 
LDL and arterial PGs in healthy state and in diabetes.  
 LDL-PG interactions have been extensively investigated for nearly four 
decades, and much progress has been made in our understanding of their 
molecular basis; still, many details of these interactions are unclear. It is well 
established that LDL-HSPG interactions are driven mainly by Coulombic attraction 
of sulfates and carboxylates of HSPG to lysine- and arginine-rich segments of 
apoB (Camejo et al., 1998; Skålen et al., 2002; Weisgraber and Rall Jr., 1987) as 
well as minor proteins such as apoE, apoJ and apoC-III (Ji et al., 1997; de Silva et 
al., 1990, Olin-Lewis et al., 2002; Hiukka et al., 2009). What is unknown is how the 
binding and release of LDL to/from HSPG affects the conformation of apoB and 
the overall particle structure and stability.  
4.1.2 Approach of the current study 
In this chapter, I focus on the initial critical step of the atherosclerotic plaque 
cascade: the binding of lipoproteins to PG. Our goal is to determine how LDL-PG 
interactions are impacted by LDL modifications during diabetes, including 






and Brownlee, 2016). To this end, we utilized heparin as a highly sulfated mimetic 
of HS; details of these macromolecules, their similarities and their differences are 
outlined in Chapter 1. In Chapter 4, we employ heparin affinity chromatography to 
isolate and characterize the heparin-bound fraction of LDL from healthy and DM2 
subjects, both treated and untreated. We determine how LDL-heparin interactions 
influence LDL structure and biochemical remodeling. We compare our resultesto 
previous studies showing that LDL interactions with heparin induce irreversible 
structural changes in apoB and influence LDL oxidation, phospholipolysis and 
fusion (Mateu et al., 1984; Camejo et al., 1991; Hurt-Camejo et al., 1992; 
Pentikäinen et al., 1997). Taken together, these findings help establish a 
mechanistic link between LDL modifications in diabetes and arterial retention of 
LDL in atherosclerosis.  
As in Chapter 3, two types of LDL samples were used. i) single-donor 
normolipidemic LDL, and ii) LDL derived from pooled plasma of DM2 patients 
before and after treatment. These LDL samples were obtained as described in 
Chapter 3, and their composition is listed in Table 3.2. Three series of  studies  
were performed. First, we determined the effects of heparin binding on the 
properties of normolipidemic LDL, including the protein conformation and particle 
susceptibility to thermal and biochemical remodeling (described in Section 4.2 
below).  Second, we determined how the heparin binding affinity is influenced by 
the biochemical remodeling of normolipidemic LDL (including hydrolysis, glycation, 






outlined in Section 4.3. This set the stage for the third series of studies where we 
analyzed heparin binding to LDL from DM2 patients (Section 4.4). I was directly 
involved in the first and third series of studies and describe them in greater detail 
in this chapter. Additional details are provided in our published results(Jayaraman 
et al., 2020).  
 
4.2 Effects of heparin binding on the properties of normolipidemic LDL 
4.2.1 Heparin affinity profile and biochemical analysis of normolipidemic 
single-donor LDL 
 Single-donor LDL from normolipidemic plasma were analyzed by heparin 
affinity chromatography as described in Chapter 2, Section 2.10. Heparin affinity 
profiles showed two peaks: the first was eluted by low-salt buffer (flow-through 
fraction) and the second was eluted by 10-30% NaCl (Figure 4.1). The second 
fraction, henceforth termed “bound”, comprised 85-90% of total LDL. Bound LDL 
were collected and immediately used for biophysical and biochemical studies. All 
data of bound LDL were recorded during the first 40 hours after elution from 
heparin affinity chromatography to minimize irreversible changes in LDL induced 
by heparin binding. During this time, the protein and lipoprotein structural integrity 
remained invariant and no changes in the LDL susceptibility to biochemical and 
physical perturbations were detected. Low amounts of non-bound LDL prevented 
their detailed studies. Therefore, as a control for the bound LDL we used native 







Figure 4.1 Heparin affinity chromatography profile of normolipidemic human 
LDL. LDL from a healthy single donor were eluted through the HiTrap heparin-
Sepharose column with 10 mM sodium phosphate buffer, pH 7.4, using increasing 
salt concentrations (0 -1 M NaCl). The dotted line shows NaCl concentration 
(100% = 1 M NaCl).  
 
4.2.2 Morphological and biochemical analyses of single-donor LDL before 
and after binding to heparin 
 Lipid levels in single-donor LDL before and after heparin binding are listed 
in Table 4.1. The results show no large differences in lipid or protein composition 









LDL  TG  PL   UC  CE 
 Protein 
Native  7.5  26.2  9.1  27.3  29.8 
Bound 6.6  25.1  8.2  27.1  32.9 
 
Table 4.1 Biochemical composition of single-donor normolipidemic plasma 
LDL before (Native) and after isolation of the heparin-bound fraction (Bound). 
Bound LDL were isolated by heparin-sepharose affinity chromatography as shown 
in Figure 4.1. The LDL isolation and biochemical analysis were performed as 
described in Chapter 2, section 2.1. Four different LDL batches were used; the 
data for batch 1 are tabulated; the results for other LDL batches were similar. CE 
- CE; UC - unesterified cholesterol; PL - phospholipids; Protein - total protein. The 
values, which represent % of total weight, show the mean of three independent 
measurements with the accuracy of ±5%.  
 
The structural integrity, size and morphology of bound LDL were 
characterized by SEC, gel electrophoresis and EM (Figs. 4.2- 4.4).  
 SEC profile of native LDL showed a major peak centered at 12 mL (Figure 
4.2). Bound LDL showed an additional population of larger particles or their 






band corresponding to larger particles or their aggregates when compared to 









Figure 4.2 Anaysis of LDL by SEC. Native and LDL bound and released from 
heparin were applied to Superpose 6 10/300 GL. Elution by phosphate buffered 
saline (10 mM Na phosphate, 150 mM NaCl, pH 7.5) was carried out at a flow rate 
of 0.5 mL/min. Native LDL (black) migrate as a single peak centered circa 12 nm. 
Arrow indicates a major additional peak seen in bound LDL (red) corresponding to 








Figure 4.3 Analysis of native and bound LDL by NDGE. Samples were resolved 
on 4-20% gradient NDGE and the gel was incubated with Instant Blue protein stain.  
Arrow indicates additional band in the bound LDL sample.  
 
Native and bound LDL were visualized by EM. Electron micrographs of 
native and bound LDL showed a relatively homogenous population of particles with 
diameters of 22-24 nm, typical of native LDL (Figure 4.4). Larger particles were not 












Figure 4.4 Electron micrographs of single-donor LDL before and after 
binding to heparin. Samples shown in Figures 4.1-4.3, were negatively-stained 
and analyzed by EM.  
  
Together, the results from SEC and NDGE suggest that bound LDL is more 
prone to spontaneous aggregation than native LDL (Figures 4.2-4.4). This is 
consistent with previous studies involving other methods showing that LDL 
became more prone to aggregation after binding to and release from HSPG in 
solution (Maor et al., 2000).  
Next, I used SDS-PAGE to test whether the heparin-induced LDL 
aggregation was accompanied by apoB fragmentation or aggregation. SDS PAGE 
revealed partial fragmentation of apoB as well as some aggregation in bound LDL 
(Figure 4.5 A). 
Next, the net charge of the native and bound LDL particles was compared 









noteworthy increase in the net negative charge, as seen by a small but significant 
shift of the bound sample towards the cathode (Figure 4.5 panel B). This shift is 
reminiscent of LDL(-), a particularly proatherogenic subclass of plasma LDL 
(Avogaro et al., 1998; Rivas-Urbina et al., 2019) that was proposed to be 
generated upon interactions of LDL with arterial HSPG in vivo (Avogaro et al., 
1998). The relevance of our in vitro studies of bound LDL to generation of LDL(-) 
in vivo is discussed in more detail in Section 4.5.4 below.  
 Taken together, our results show that brief binding to and release from 
heparin induces rapid biochemical modifications in plasma LDL. These 
modifications include partial apoB fragmentation seen by SDS PAGE (Fig. 4.5 
panel A), apoB aggregation seen by SEC and SDS PAGE (Figs. 4.2 and 4.5 panel 
A), as well as a small increase in the net negative charge on LDL particles seen 








Figure 4.5 SDS PAGE and agarose gel electrophoresis of single-donor LDL 
before and after binding to heparin. A. SDS PAGE of native and bound plasma 
LDL. The band for apoB is labelled. Gel stained with Instant Blue. B. Agarose gel 
electrophoresis of native and bound LDL stained with Instant Blue. Human plasma 
HDL from the same donor are shown for comparison.  
 
4.2.3 Spectroscopic analysis of plasma LDL before and after binding to 
heparin 
 To explore whether heparin binding and release involves conformational 
changes in apoB, we used CD, absorption and fluorescence spectroscopy 
monitoring tryptophan (Trp) emission. Far-UV CD spectra of bound LDL showed 







the CD amplitude at short wavelengths (< 200 nm), which was accompanied by 
increased noise at these wavelengths (Figure 4.7). This finding suggests increased 
UV light scattering from large particles and their aggregates (~100 nm), which 
increases at short wavelengths when the particle size approaches the wavelength 
of light (e.g. <200 nm in far-UV) (Mao and Wallace, 1984).  This result was 
consistent with increased aggregation of bound LDL observed by SEC and NDGE 
(Figs. 4.3 and 4.4).  
 According to far-UV CD spectra, there were no major protein secondary 
structure differences between native and bound LDL (Figure 4.6) 
Compared to native LDL, Trp emission spectra of bound LDL showed a 
decreased amplitude but no changes in the wavelength of maximal fluorescence. 
The latter suggests that heparin binding did not induce major changes in the 
polarity of the microenvironment of Trp residues in apoB. Decreased emission 
intensity in the intrinsic Trp fluorescence is likely due to increased sample turbidity, 
which is consistent with our CD and absorption spectroscopic results that also 
suggest increased turbidity (Figure 4.7).  
Compared to native LDL, UV absorption spectra of bound LDL showed a 
small increase in the signal at 280 nm and a progressive signal increase upon 
decrease in wavelength from 350 to 250 nm (Figure 4.8). This effect is consistent 
with increased turbidity, i.e. increased light scattering of the aggregated particles, 
which is most pronounced at shorter wavelengths (i.e. when the wavelength of UV 






Together, the spectroscopic data in Figures 4.6-4.8 provided no direct 
evidence for the overall conformational changes in apoB on bound LDL, such as 
the secondary structural unfolding or altered tryptophan environment. However, 
bound and native LDL showed significant spectral differences in far-UV CD, 
absorbance and Trp fluorescence. These differences were consistent with 






Figure 4.6 Secondary structure of single-donor LDL before and after binding 
to heparin monitored by far-UV CD spectrometry. The spectra were recorded 
at 190- 250 nm, 25 °C. Native (black) or bound (gray) LDL in 10 mM sodium 









Figure 4.7 UV absorption spectra of native and bound plasma LDL. The 
spectra were recorded at 250–450 nm using Varian-3500 spectrophotometer 
(Agilent). Samples were single-donor plasma LDL, either native (black) or bound 











Figure 4.8 Tryptophan emission spectra of single donor plasma LDL. Native 
(black) or bound (gray) LDL in 10 mM sodium phosphate buffer, pH 7.4 were 
analyzed. Intrinsic Trp fluorescence spectra were recorded at 305–400 nm with λex 
= 295 nm and 5 nm excitation and emission bandwidths. 
 
 
4.2.4 Susceptibility of LDL to proteolytic cleavage before and after heparin 
binding 
 As an alternative approach to investigate conformational changes in apoB 
in bound LDL, limited proteolysis was performed using MMP-12 and plasmin. 
Native LDL and LDL that was bound and released from heparin were incubated 
with either MMP-12 or plasmin for 3 hours at 37° C.  The reaction was stopped, 
and the samples were analyzed by SDS PAGE. Figure 4.9 shows that both MMP-










was not proteolyzed under these conditions. Therefore, binding to heparin makes 
apoB more susceptible to cleavage at basic, aliphatic, aromatic and Pro residues. 
This suggests increased solvent accessibility of various charged or polar residues, 
as well as hydrophobic regions in apoB. This finding is consistent with previous 
studies showing that LDL released from complexes with arterial PG or other GAGs 
becomes more susceptible to enzymatic digestion by exposing charged or polar 









Figure 4.9 Proteolysis of plasma LDL by MMP-12 and plasmin before and 
after heparin binding and release. Native and bound LDL samples were 
incubated for 3 hours at 37°C with either MMP-12 or plasmin (200:1 
substrate:enzyme wt/wt), in 10 mM sodium phosphate buffer, pH 7.4. The reaction 
was stopped by adding 1 mM phenylmethylsulfonyl fluoride for plasmin or 50 mM 
EDTA for MMP-12. Samples were resolved on SDS PAGE and gels incubated with 
InstantBlue to stain protein bands. The apoB band is labeled.  
 
4.2.5 Analysis of apoB conformation in native and bound LDL using 
antibodies  
 Although limited proteolysis studies by us (Figure 4. 9) and others (Camejo 








changes in apoB, the location of these changes in the apoB molecule was 
unknown. In an attempt to localize these conformational changes to specific apoB 
regions, we explored antibody binding to native and bound LDL.  Four antibodies 
specific for different regions of apoB, were used. Figure 4.10 shows the epitope 
map for the antibodies used in our analysis (bottom), along with the location of the 
inferred heparin binding sites (middle) and the linear domain structure proposed 
for apoB (top). Seven heparin-binding sites have been identified in human apoB 
by using a combination of cyanogen bromide and proteolytic digestion with heparin 
affinity chromatography (Weisgraber and Rall,1987). These include: site A 
(residues 5-99); site B (residues 205-279); site C (residues 875-932); site D 
(residues 2016-2151); site E (residues 3134-3209); site F (residues 3356-3489); 
and site G (residues 3659-3719) (Figure 4.10, middle panel). Epitopes of one of 
the antibodies used in our study, C1.4, overlapped with the heparin binding sites 
A and B in apoB (Fig. 4.10).  
Figure 4.11 shows that there were no major differences in the antibodies 
binding to native vis a vis bound LDL. Hence, I was not able to identify specific 
regions that underwent major structural changes upon heparin binding from this 
experiment.  
There could be several reasons for this negative outcome. First, it is 
possible that Western blottingwas not a sensitive enough technique for 






analysis such as competitive enzyme-linked immunosorbent assay (ELISA) could 
be used to overcome this limitation.  
Second, it is possible that the epitopes that were available for binding of 
antibodies did not significantly overlap with apoB regions that undergo major 
structural changes upon heparin binding. This problem could be overcome by 
using a different subset of antibodies including those targeting apoB regions that 
have been previously shown to bind heparin. In particular, sites E and F, which 
contain short regions rich in basic residues, were proposed to be mainly 
responsible for the heparin binding by apoB (Weisgraber and Rall, 1987). I 
hypothesize that targeting these sites using antibodies in future studies may help 










Figure 4.10 Linear representation of apoB domains, heparin binding sites 
and antibody binding sites.  
Top: Schematic representation of the pentapartide structure of apoB. On the basis 
of the amino acid sequence analysis and low-resolution structural studies, apoB 
has been proposed to contain five domains with alternating α-helical and β-sheet 
regions, designated as βα1, β1, α2, β2, and α3 (Cladaras et al., 1986; Segrest et 
al., 1994). Residue numbers delineating individual domains are indicated.  
Middle: Location of the seven heparin binding sites in apoB proposed by 
Weisgraber & Rall (1987).  
Bottom: The epitope map for the monoclonal antibodies used in this work; C1.4, 
Mb18, 4f6 and Bsol7. The antibodies were generated in the laboratory of Dr. Yves 








Figure 4.11 Western blots of native and bound plasma LDL probed with 
Mb18, Bsol7, 4F6, C1.4. Six µL of native and bound plasma LDL were resolved 
by NDGE, then electrotransferred to polyvinylidene fluoride membrane. The 
membrane was probed with the primary antibodies as listed.  
 
4.2.6 Analysis of LDL susceptibility to thermal and lipolytic remodeling 
before and after heparin binding 
To determine whether heparin binding increases LDL susceptibility to other types 
of structural or biochemical remodeling, we used native and bound LDL in the 
following experiments. First, we explored thermal remodeling, which leads to 
irreversible lipoprotein aggregation, fusion and disintegration (Lu et al., 2012; Lu 
et al., 2013). Next, we explored mild lipolytic remodeling by sphingomyelinase 
(SMase) and phospholipase C (PLC). In vivo, both SMase and PLC are known to 
remodel LDL and promote their aggregation, which potentially contributes to 








used these enzymes to compare susceptibility of native and bound LDL to lipolytic 
remodeling.  Absorption spectroscopy was used as a readout of LDL remodeling 
to monitor changes in turbidity upon increase in the particle size due to aggregation 
and fusion, as outlined in Chapter 2, section 2.4.   
            First, we explored the effect of heating on native and bound LDL. 
Compared to native LDL, thermal remodeling of bound LDL shifted to lower 
temperatures, as evident from a shift in the thermal denaturation curves of the 
bound sample by about 10°C compared to the native sample (Figure 4.12). This 
result shows that LDL binding to heparin decreases the thermal stability of LDL.  
   Next, the lipolytic remodeling by SMase and PLC of native and bound LDL 
was explored by Dr. Jayaraman using a 200:1 substrate:enzyme weight ratio. The 
degree of SMase-induced lipolysis was determined by measuring the amount of 
phosphocholine, which is generated upon lipolysis of sphingomyelin, using an 
Amplex Red sphingomyelinase assay kit. The degree of PLC-induced lipolysis was 
monitored by measuring the loss of phospholipids using an EnzyChrom 
phospholipid assay kit. This analysis showed that 20–25% of lipids in single donor 
native LDL were hydrolyzed. The time course of LDL remodeling due to 
aggregation and fusion upon lipolysis was monitored by absorbance (turbidity). 
During 1 hour of lipolysis at 37°C, both native and bound LDL showed major 
remodeling, but in the bound LDL the remodeling was faster. Bound LDL, also 
showed a larger increase in turbidity (i.e. more extensive aggregation upon 






 In summary, our results showed that LDL undergoes irreversible structural 
changes upon binding to heparin. These changes make LDL more susceptible to 
a wide range of perturbations, including thermal (Figure 4.12) and hydrolytic 
remodeling by proteases such as MMP-12, plasmin (Figure 4.9) and lipases such 
as SMase and PLC (Figure 4.13). This is consistent with previous studies showing 
that, upon binding to arterial HSPGs, LDL becomes less stable and more 
susceptible to biochemical (proteolysis, lipolysis, oxidation) and structural 
remodeling (Camejo et al., 1998; Mateu et al., 1984; Hurt-Camejo et al., 1992). 
Our studies involving heparin binding are consistent with previous studies, which 
used arterial PGs and HSPGs (Camejo et al., 1988; Skålen et al., 2002; Khalil et 
al., 2004). Thus, heparin-LDL binding provides a useful model system for 






Figure 4.12 Thermal remodeling of native and heparin-bound LDL. Samples 
used in this experiment were single-donor plasma LDL in 10 mM sodium 
phosphate buffer, pH 7.4. Native LDL is in black, bound LDL in red. Samples were 
heated from 10°C to 95°C at a constant rate of 1°C/minute with a 10 second 
accumulation time. The reaction was monitored by absorbance (turbidity) at 280 











Figure 4.13 Lipolytic remodeling of native and heparin-bound LDL by SMase 
and PLC. Plasma LDL were incubated for 3 hours at 37 °C in buffer C (150 mM 
NaCl, 2 mM CaCl2, 20 mM Tris HCl, pH 7.0) containing either 40 μg/mL SMase or 
500 mU/mL PLC. The buffer for the SMase reaction also contained 2 mM MgCl2 
and 50 μM ZnCl2. lipolysis was stopped by adding EDTA to a final concentration 
of 10 mM, whereupon LDL were re-isolated by SEC. The reaction time course was 
monitored continuously by turbidity (absorbance) at 450 nm. Native LDL is in black, 
and bound LDL is in red.  
 
4.2.7 Controls to test for potential artifacts in the preparation of bound LDL 
 A series of control experiments were performed by Dr. Shobini Jayaraman 
using single-donor normolipidemic LDL to determine if isolation of bound LDL by 
heparin affinity chromatography produced experimental artifacts. Such artifacts 







the column or from high salt that was used to elute bound LDL from the heparin 
column.   
First, LDL were eluted via the Hi-trap Blue HP Sepharose column in the 
same binding buffer as that used with heparin affinity (10 mM sodium phosphate, 
pH 7.4) to determine if this caused any irreversible changes in the lipoprotein. The 
LDL peak fraction was collected and analyzed by electron microscopy, NDGE, 
SDS PAGE, agarose gel electrophoresis, far-UV CD and thermal denaturation. 
These analyses revealed that LDL eluted from the Sepharose column showed no 
changes in the protein integrity,particle size distribution, or aggregation 
(Jayaraman et al., 2020). Therefore, LDL interactions with the Sepharose itself did 
not impact the results of our experiments.  
 Second, to determine if exposure to high salt irreversibly altered LDL, LDL 
were pre-incubated in a high-salt solution to mimic the conditions used to elute the 
bound LDL fraction from heparin-Sepharose. LDL (0.5 mg/mL protein) were 
incubated in 10 mM sodium phosphate, pH 7.4, containing 0.5 M NaCl at 37 °C for 
6 hours, followed by dialysis against low-salt buffer. Exposure to high salt did not 
cause any irreversible changes in the structure or stability of LDL particles 
(Jayaraman et al., 2020).   
 Third, LDL were incubated with heparin sodium salt to determine the effects 
of heparin in solution on LDL structure and stability. LDL (0.5 mg/mL apoB) were 
incubated in solution containing 0.5 mg/mL heparin sodium salt in 10 mM PBS, pH 






acid content and turbidity measurements were performed before and after 
incubation. No significant protein structure or particle differences were found 
between intact and heparin-bound LDL (Jayaraman et al., 2020).  
However, the presence of heparin salt in solution influenced: i) tryptic 
digestion of apoB on LDL monitored by SDS PAGE; ii) secondary structure of apoB 
monitored by far-UV CD; iii) thermal denaturation monitored by absorbance, and 
iv) LDL phospholipid oxidation in the presence of 10 µM CuSO4 monitored by 
absorbance at 234 nm. Thus, incubation of LDL with heparin salt showed 
decreased secondary structure of apoB, decreased thermal stability and increased 
susceptibility to tryptic digestion and oxidation (Jayaraman et al., 2020).   
 In summary, these control experiments showed that LDL interactions with 
Sepharose or exposure to high NaCl concentrations were not responsible for our 
findings. However, similar to LDL interactions with heparin immobilized on 
Sepharose, LDL interactions with heparin salt in solution were destabilizing. This 
is consistent with direct destabilizing effect of heparin on LDL reported previously 
(Mateu et al., 1984; Camejo et al., 1991; Hurt-Camejo et al., 1992; Pentikäinen et 
al., 1997; Hakala et al., 1999). Together, our studies consistently show that 
irreversible structural changes observed in bound LDL result from specific 







4.3 Heparin binding of in vitro-modified LDL mimicking modifications 
occurring in diabetes  
4.3.1 Effects on lipolysis, proteolysis and oxidation   
 Previously, we showed that mild lipolysis and oxidation decrease the 
structural stability of LDL and promote LDL aggregation (Jayaraman et al., 2007). 
In diabetes there is an upregulation of enzymes which promote lipolysis and 
proteolysis of proteins damaged by the many changes induced by diabetes 
(increase in reactive oxygen species, mitochondrial oxidation, etc.). Additionally, 
these enzymes function to degrade pro-inflammatory cytokines, and act on plasma 
lipoproteins to alter their lipid composition and overall particle structure (Shah and 
Brownlee 2016). Diabetes is also associated with oxidative stress that leads to 
increased oxidation of circulating lipoproteins (Aronson 2008; Edwards et al., 
1999). We asked how lipoprotein modifications that are enhanced in diabetes, 
including lipolysis, proteolysis and oxidation, will affect LDL binding to HSPG, and 
how the LDL particles may be changed after their release from HSPG. 
 Through a series of carefully controlled experiments, Dr. Jayaraman 
modified LDL in vitro to produce particles which had undergone lipolysis, 
proteolysis and oxidation to various stages, from mild to moderate, to mimic LDL 
remodeling in vivo. She then analyzed these modified particles using heparin 
affinity chromatography. She showed that lipolysis, oxidation and proteolysis 
enhance the binding of LDL particles to heparin and destabilize the particle in a 






the reciprocal relationship between LDL remodeling in diabetes and increased LDL 
affinity for heparin. 
4.3.2 Effects of LDL glycation on heparin binding  
 Increased glycation of plasma proteins and lipoproteins is a hallmark of 
diabetic hyperglycemia. LDL glycation, which occurs at specific sites in apoB and 
phospholipids, alters structural and functional properties of LDL. These 
modifications enhance LDL proatherogenic potential through several mechanisms 
including increased arterial retention (Aronson et al., 2008; Shah et al., 2016; 
Tannock et al., 2008; Edwards et al., 1999; Hagensen et al., 2019; Stirban et al., 
2013). It was shown in vivo that apoB in diabetes contains a higher proportion of 
lysine-bound glucose when compared with apoB isolated from nondiabetic 
individuals (1.9 versus 0.5 mol glucose/mol protein, respectively) (Schleicher et al., 
1981). However, it is not yet known which lysines are glycated in the normal state 
and in diabetes (Younis et al., 2008). Lipoprotein glycation in vivo is a complex 
process usually accompanied by oxidation, termed glycoxidation (Stirban et al., 
2013; Soran et al., 2011). This complexity, together with altered biochemical 
composition in diabetic LDL (described in parts 4.9 and 4.10 below) makes it 
difficult to discern the effects of glycation alone on the LDL properties.  
In an effort to dissect the effect of LDL glycation on heparin binding, LDL 
from healthy donors were used in two types of in vitro experiments performed by 






with oxidation.  The details of these experiments are described in our paper 
(Jayaraman et al., 2020). Here, I summarize the key results.  
First, I briefly describe the results of controlled glycation under non-oxidative 
conditions, which was performed by incubating LDL with glucose under carefully 
controlled anaerobic conditions to generate gly-LDL. For comparison with gly-LDL, 
Dr. Jayaraman used native LDL and control LDL (termed ctr-LDL) that were 
incubated similarly to gly-LDL, but without the glucose.  
The heparin affinity profile of the gly-LDL showed that it bound more 
strongly to heparin than the native and control LDL i.e. gly-LDL eluted at a higher 
NaCl concentration, ~50% NaCl in gly-LDL vs. 30% in native or ctr-LDL (Figure 
4.15). Stronger binding to heparin could potentially result from the conformational 
changes in apoB induced by glycation, which exposes more heparin binding sites 
on the apoB surface.  
Dr. Jayaraman used several methods including Far-UV CD, SDS PAGE, 
NDGE and agarose gel electrophoresis, to test for potential structural changes in 
apoB on gly-LDL. Far-UV CD spectra of gly-LDL did not show any major changes 
in the protein secondary structure when compared to native and control LDL. Next, 
SDS PAGE was used to determine if apoB on gly-LDL showed increased 
fragmentation. This analysis showed no significant differences between gly-LDL 
and the native and control LDL. Similarly, NDGE showed no changes in the particle 
size of gly-LDL compared to the native and control LDL. Agarose gel showed a 






shift in the LDL band towards the cathode. This shift reflects loss of positive charge 
on Lys upon glycation (Jayaraman et al., 2020). 
Next, Dr. Jayaraman tested the susceptibility of the gly-LDL to limited 
proteolysis. LDL samples were incubated with trypsin for 1 hour and then analyzed 
by SDS PAGE. Importantly, gly-LDL were more susceptible to proteolysis 
compared to native or control LDL (Jayaraman et al., 2020). This result verified the 
hypothesis that glycation induces significant conformational changes in apoB. 
Complementary to the study of glycation of plasma LDL in a non-oxidative 
setting, Dr. Jayaraman also performed LDL glycation experiments accompanied 
with particle oxidation i.e. glycoxidation. Plasma LDL were incubated for one to six 
days with methylglyoxal, a highly reactive glycating agent that can form during 
oxidative stress in patients with type-II diabetes mellitus (Rabbani et al., 2011). 
The heparin affinity profile of minimally modified glycoxidated LDL showed a peak 
shift for bound LDL to high salt, indicating increased affinity for heparin (Jayaraman 
et al., 2020).  
In summary, results revealed that LDL glycation and glycoxidation in vitro 
increase the affinity of bound LDL for heparin (Jayaraman et al., 2020). These 
studies set the basis for interpretation of the effects of heparin binding on diabetic 








Figure 4.14 Heparin affinity increases upon LDL glycation in vitro. LDL 
glycated without oxidation (gly-LDL), native LDL (nat-LDL) and control LDL 
incubated without glucose (ctr-LDL) was loaded onto the HiTrap heparin 
Sepharose column using a buffer with increasing salt concentration (10 mM 
sodium phosphate, pH 7.4, 0-1 M NaCl). 
 
 
4.4 Effects of diabetes on LDL-heparin interactions and LDL properties 
4.4.1 Heparin binding of LDL from healthy and diabetic patients 
       Finally, diabetic LDL binding to heparin was explored. LDL were isolated from 
plasma pooled from three patients' cohorts: healthy normolipidemic subjects (Nl), 
untreated patients newly diagnosed with DM2 with poor glycemic control (Pc, 
HbA1c ≥ 7%), and diabetic patients whose treatment resulted in improved glycemic 








in Chapter 3, section 3.3.1; lipoprotein biochemical composition is listed in Table 
3.2.  
 As discussed in the previous section, our group and others have shown that 
increased in vitro glycation increases LDL binding to heparin, apparently via 
conformational changes in apoB, and increased propensity of LDL aggregation 
and susceptibility to lipolysis and proteolysis. These changes are potentially pro-
atherogenic. We hypothesized that in diabetes, increased LDL glycation along with 
other LDL changes (such as oxidation) cause similar pro-atherogenic changes, 
which might provide mechanistic links between diabetes and atherosclerosis. To 
test this idea, we performed a series of studies described below. 
 First, we tested the effects of diabetes, treated and untreated, on the 
heparin binding of LDL. The heparin affinity profiles revealed a striking difference 
between the samples: while Nl-LDL and Gc-LDL showed similar profiles, with only 
a slight peak shift in bound Gc–LDL towards higher salt (higher affinity for heparin), 
bound Pc-LDL showed a much larger shift, from about 0.3 M to 0.6 M NaCl, 
indicating a large increase in heparin binding affinity (Figure 4.15). Thus, LDL from 
patients with diabetic hyperglycemia bind heparin more strongly.  Similarly, 
previous studies reported increased binding to arterial PG of LDL from 
hyperglycemic DM2 patients; moreover, LDL binding was restored to normal levels 
upon successful treatment of hyperglycemia (Edwards et al., 1999; Hagensen et 






Figure 4.15 Heparin affinity profile of pooled LDL samples from Nl, Pc and 
Gc groups. LDL were loadedonto HiTrap heparin-sepharose column, and eluted 
with a buffer containing increasing salt concentration (10 mM sodium phosphate 
buffer, pH 7.4, containing 0 -1 M NaCl). The dotted line shows NaCl concentration 
(100% = 1 M NaCl). Nl (normolipidemic) LDL is in black, Gc (good glycemic control) 
is in purple, and Pc (poor glycemic control) is in magenta.  
 
LDL isolated by heparin affinity chromatography were visualized by electron 
microscopy (Figure 4.16). As expected, native Nl-LDL, Gc-LDL and Pc-LDL 
displayed similar size and morphology. Furthermore, the size and morphology of 
native and bound Nl-LDL and Gc-LDL were similar. In stark contrast, bound Pc-
LDL showed not only intact-size LDL but also smaller and larger particles that were 
products of lipoprotein disintegration and fusion (Figure 4.16, bottom right). 
Therefore, upon binding to heparin, Pc-LDL became structurally labile, and a 








combined effects of hyperglycemia and heparin binding are especially 
destabilizing and cause LDL disintegration and fusion.  
To our knowledge, this effect has not been previously reported. It is 
consistent with the lipid phase separation observed in LDL-PG complexes over 
time (Mateu et al., 1984), indicating that LDL in such complexes gradually 
disintegrate, fuse and coalesce into lipid droplets. 
Our results suggest that LDL that bind heparin more strongly disintegrate 
faster upon such binding (Figure 4.16). These findings also show that LDL from Pc 
patients with diabetic hyperglycemia bind more strongly to heparin, but the binding 
can be restored upon treatment that normalizes glycemic control in Gc patients 
(Figure 4.15). 
Together, our experiments (Figures 4.14-4.16) showed that in vitro LDL 
glycation without detectable oxidation greatly increased heparin binding affinity of 
LDL (Figure 4.1). Conformational changes in apoB upon glycation and mild 









Figure 4.16 Electron micrographs of negatively-stained Nl-LDL, Pc-LDL and 
Gc-LDL before (native) and after binding to and release from heparin 
(bound). Scale bar = 60 nm.  
 
4.4.2 Effects of diabetic hyperglycemia on the structural and biochemical 
properties of LDL 
 To better understand why Pc-LDL bind heparin more strongly and become 
structurally labile upon such binding, we investigated the effects of diabetic 
hyperglycemia on the structural properties of LDL by using CD and Trp 
fluorescence spectroscopy.   
 Far-UV CD spectra of Nl-LDL, Gc-LDL and Pc-LDL showed that the well-
ordered secondary structure of apoB decreased in Pc-LDL. The secondary 






Trp emission spectra of all LDL samples showed a similar wavelength of maximal 
fluorescence at ~330 nm, indicating largely buried Trp, but only Pc-LDL showed a 
reduced emission intensity consistent with less well-ordered apoB conformation 
(Figure 4.17 B). Together, these spectroscopic data showed that the protein 






















Figure 4.17 Far-UV CD and Trp emission spectra of Nl-LDL, Gc-LDL and PC-
LDL. A Far-UV CD spectra were recorded from 190–250 nm at 25°C. B  Intrinsic 
Trp fluorescence spectra were recorded at 25°C at 305–400 nm with λex = 295 nm 
and 5 nm excitation and emission bandwidths. 
 
 Next, the effects of diabetic hyperglycemia on the biochemical properties of 
LDL were investigated by using agarose gel, NDGE and SDS PAGE. Agarose gel 
electrophoresis showed no differences in the overall net charge of Nl-LDL, Gc-LDL 
and Pc-LDL (Figure 4.18 panel A). Similarly, NDGE showed no differences in the 
particle size (Figure 4.18 panel B) and SDS PAGE showed no major differences 
in the protein fragmentation or aggregation (Figure 4.18 panel C). Hence, agarose, 
NDGE and SDS PAGE did not detect any major differences between Nl-LDL, Gc-











Figure 4.18 Agarose gel, NDGE and SDS PAGE of Nl-LDL, Gc-LDL and PC-
LDL. A Agarose gel electrophoresis, LDL samples (4 μg protein per lane) were 
loaded on 0.5% agarose gel. B NDGE, 4–20% loaded with 6 μg protein per lane. 
C SDS PAGE, 4% Tris-glycine, loaded with 5 μg protein per lane. The gels were 
incubated with InstantBlue protein stain to visualize proteins. 
 
To complement spectroscopic studies, apoB conformation was further 
explored by Dr. Jayaraman using limited proteolysis by trypsin, plasmin or MMP-
12. SDS PAGE revealed that all three proteases caused extensive apoB 
fragmentation in Pc-LDL, while apoB in Nl-LDL and Gc-LDL under similar 
conditions remained intact (Jayaraman et al., 2020). Therefore, apoB on Pc-LDL 
underwent conformational changes that decreased its protection from proteolysis, 
but in Gc-LDL the protein protection was restored. This conclusion was consistent 
with far-UV CD spectra showing that the well-ordered secondary structure of apoB 








In summary, our results showed that DM2 patients with untreated 
hyperglycemia (the Pc group) have LDL that are distinct from the Nl and Gc 
counterparts. Pc-LDL showed: increased binding affinity to heparin (Figure 4.15) 
which promotes particle disintegration and fusion (Figure 4.16); loss of ordered-
secondary structure in apoB evident from far-UV CD spectra (Figure 4.17 panel 
A);higher susceptibility to proteolysis and lipolysis (Jayaraman et al., 2020). All of 
these properties are expected to be pro-atherogenic. 
 
4.5 Conclusions 
4.5.1 Main findings of this study  
 This chapter reports a systematic analysis of mutual effects of LDL-heparin 
binding on the biochemical and structural properties of human LDL. The main 
findings are: i) binding to heparin alters the structure of apoB on LDL making LDL 
more susceptible to hydrolytic and oxidative modifications; ii) conversely, 
hydrolytic and oxidative modifications in LDL cause structural disorder in apoB that 
increases its affinity for heparin; iii) the affinity for heparin is higher in LDL from 
hyperglycemic DM2 patients as compared to healthy and normoglycemic subjects. 
Furthermore, this study reinforces the link between irreversible LDL modifications 
upon HSPG interactions and the formation of electronegative LDL found in blood 






4.5.2 Heparin affinity chromatography as a tool to study lipoprotein-HSPG 
binding 
 We used heparin-Sepharose affinity chromatography to isolate LDL after 
binding to heparin, and also as an analytical tool to detect modified lipoproteins 
differing in their heparin binding affinity. Biological relevance of the heparin affinity 
chromatography is underscored by our finding that LDL from hyperglycemic 
patients bind heparin more strongly than their normoglycemic counterparts (Pc-
LDL compared to Nl-LDL and Gc-LDL, Figs. 4.15-4.18).  A similar finding was 
reported in previous studies that used PG isolated from rabbit aorta and quantified 
binding by LDL precipitation (Edwards et al., 1999; Edwards et al., 2002). In our 
study we quantified LDL binding to heparin using affinity chromatography. Despite 
different approaches and different cohorts of patients in these studies, the heparin 
binding trends observed for LDL from untreated and treated DM2 patients and 
normolipidemic controls were very similar. This similarity suggests that heparin 
affinity chromatography is useful for identifying LDL properties that importantly 
influence the pro-atherogenic binding to arterial HSPGs and for determining how 
LDL modifications in diseases such as diabetes affect the binding.  
 
4.5.3 Role of structural disordering in apoB and other factors that enhance 
binding of LDL to PG in diabetes 
 Previous studies have established that LDL interactions with the PG matrix 






interactions are augmented by LDL modifications in diabetes; in turn, LDL-PG 
interactions induce irreversible morphological and biochemical changes in LDL 
(Camejo et al., 1998; Skålén et al., 2002; Khalil et al., 2004), although the order of 
these changes was unclear. Our results, in combination with previous findings, 
suggest that conformational changes in apoB initiate the binding and are also an 
early irreversible step that occurs in LDL after binding and release from HSPGs. 
This early step is followed by increased oxidation, hydrolysis and aggregation of 
LDL, all of which are pro-atherogenic.  
 Both previous and current studies of diabetic LDL showed that restoration 
of the glycemic control upon various therapies restored the heparin binding affinity 
of the patients’ LDL (Figure 4.15), even though the lipid profiles were only partially 
restored (Table 3.2) (Edwards et al., 2002). This prompted Edwards and 
colleagues to propose that increased binding of hyperglycemic LDL to arterial PG 
is due solely to increased glycation of apoB (Edwards et al., 2002).  
Our results appear consistent with this idea. We show that in vitro glycation 
and glycooxidation of LDL enhanced the binding affinity to heparin (Figures 
4.14and 4.15 and supplemental figure S9M in Jayaraman et al., 2020). However, 
such results should be interpreted with caution, since LDL glycation in vitro is more 
extensive than that in vivo and generates different products; in particular, LDL 
glycated in vitro and in vivo show increased exposure of different apoB epitopes 
(Braschi et al., 2006), reflecting conformational differences in apoB which may 






wherein various modifications in diabetic LDL potentially contribute to its increased 
heparin binding affinity. These modifications can include not only glycation but also 
mild oxidation as well as hydrolysis of surface lipids, which increase LDL binding 
to heparin in vitro (Jayaraman et al., 2020). Such oxidative and hydrolytic 
modifications are increased in DM2 but are largely restored upon therapy that 
optimizes patients’ glycemic control (Jayaraman et al., 2020). Taken together, the 
results of this and previous studies suggest a multifaceted mechanistic link 
between enhanced arterial retention of LDL in diabetes and specific LDL 
modifications such as glycation, mild oxidation and phospholipid lipolysis.   
 An important trend demonstrated in our study is that modifications that 
increase LDL affinity for heparin are accompanied by increased solvent 
accessibility of apoB and its structural disordering. This manifests as increased 
susceptibility to proteolysis (Figs. 4.9 and 4.13), thereby providing a useful means 
to assess structural changes in this large lipid-bound protein. In several instances, 
loss of ordered secondary structure in apoB can also be detected by far-UV CD 
spectroscopy (Figs. 4.6 and 4.17). 
 Together, our results compel us to propose that mild oxidation, glycation 
and hydrolysis of surface lipids induce irreversible conformational changes in 
apoB. These changes increase solvent exposure of apoB, making it more 
susceptible to proteolysis and probably unmasking additional heparin binding 
sites. Conversely, LDL binding to heparin causes irreversible biochemical and 






probably stem from the increased solvent exposure of apoB that becomes more 
susceptible to proteolysis (Figure 4.9). We hypothesize that binding to heparin lifts 
parts of apoB off the lipid surface, thereby increasing the solvent accessibility of 
both the protein and the lipid moieties, which promotes their hydrolysis and 
oxidation, while also decreasing the structural stability of the LDL assembly 
(Figures 4.12 and 4.13).  
This idea is consistent with heparin-induced dissociation of small 
apolipoproteins such as serum amyloid A from the HDL surface, which was 
proposed to contribute to the development of the inflammation-linked amyloidosis 
(Noborn et al., 2012). Due to its large size and hydrophobicity, full-length apoB 
does not completely dissociate from LDL upon binding to heparin or PGs. 
However, the results reported in this chapter suggest that increased solvent 
exposure of apoB upon such binding triggers biochemical and structural changes 
in LDL that are expected to contribute to the development of atherosclerosis.  
 
4.5.4 Relevance to pro-atherogenic electronegative LDL  
 The results presented here suggest that, after binding to heparin, 
LDL acquires properties resembling those of electronegative LDL, termed LDL(-). 
LDL(-)  is a minor fraction of modified LDL first reported by Avogaro (Avogaro et 
al., 1988). This heterogeneous fraction is modified by mechanisms such as 
lipolysis and oxidation, which results in the common feature of increased 






patients, but increases in disease conditions. Patients with even a slight increase 
in electronegative LDL have an increased risk for cardiovascular disease (Ivanova 
et al., 2015, Chan et al., 2013). LDL(-) has inflammatory properties similar to 
oxidized LDL e.g., they promote the release of inflammatory cytokines by 
leukocytes and endothelial cells (Estruch et al., 2013). There is also a higher 
content of TG (De Castellarnau et al., 2000), FFA, lysophosphatidylcholine 
(Benítez et al., 2004) and ceramide (Estruch et al., 2013) in LDL(-) compared to 
normal LDL.  
Since LDL(-) are particularly proatherogenic, the importance of our findings 
is in reinforcing the mechanistic link between LDL modifications, which are 
increased in diabetes and augment LDL-PG interactions, and atherosclerosis. 
Similar to bound LDL, LDL(-) are more heterogeneous in size, contains more FFA, 
and are more susceptible to oxidation, proteolysis, lipolysis, structural 
destabilization and aggregation as compared to native LDL (Rull et al., 2016; 
Rivas-Urbina et al., 2019). Moreover, LDL(-) have increased affinity for PGs, and 
the levels of LDL(-) increase in DM2 patients but decrease upon improvement of 
their glycemic control (Rivas-Urbina et al., 2019). Although in the series of 
experiments presented in this chapter we used heparin rather than PG from the 
arterial wall, the similarity between our results and those of Camejo’s group using 
PGs (Camejo et al., 1991) suggests that circulating LDL(-) may originate, at least 
in part, from LDL that enter the arterial wall, interact with PGs, and then return to 






their first report describing LDL(-) (Avogaro et al., 1988), but its testing proved 
problematic. The results reported here strongly support this idea and help explain 






5.1 Summary of Chapters 3 and 4 
 The results reported in this dissertation and in our publications have 
elucidated novel details regarding lipoprotein stability in atherosclerosis and 
diabetes. It was well-known that elevated plasma levels of circulating TG are a 
hallmark of diabetes and a risk factor for atherosclerosis (Sarwar et al. 2007; 
Talayero & Sacks, 2011; Nordestgarrd & Varbo, 2014). However, the molecular 
details of how an increase in TG affects structural stability and remodeling of its 
major plasma carriers, LDL and VLDL, was unknown. Our studies described in 
Chapter 3 showed that an increase in TG levels in the core of LDL and VLDL 
reduces lipoprotein stability and promotes particle remodeling, fusion, rupture and 
aggregation; all of these changes are pro-atherogenic. In the first series of 
experiments, we explored lipoproteins from healthy subjects with variations in TG 
levels that occurred either naturally or upon addition/removal of TG in vitro. Next, 
we expanded the studies to lipoproteins from DM2 patients in collaboration with 
the laboratory of Dr. Jose Luis Sanchez-Quesada. From these combined studies, 
we learned that increased TG levels in plasma LDL and VLDL, which occur in DM2 
patients contribute to destabilization of these lipoproteins and thereby enhance 






In the second project described in Chapter 4, we provided clear evidence 
that LDL binding to and release from heparin promotes irreversible biochemical 
and biophysical changes, which can be detrimental to the particle integrity. Brief 
interactions with heparin produced modified LDL with increased susceptibility to 
thermal denaturation, lipolysis, proteolysis, and further destabilization after 
oxidation and glycation. All these LDL modifications are pro-atherogenic. Notably, 
these pro-atherogenic effects of binding to heparin were exacerbated in LDL from 
DM2 patients. These findings provide sharper insights into the initial step in the 
response-to-retention hypothesis, which is the binding of plasma LDL to the HSPG 
of the arterial intima. Moreover, they strongly support the idea that LDL (-), which 
is a minor highly pro-atherogenic subclass of plasma LDL, originates from LDL that 
have been bound to HSPG in the arterial wall and then released into circulation 






 Chapters 3 and 4 provide mechanistic links between diabetes and 
atherosclerosis. In both projects, our EM images beautifully complement and 
illustrate the results of the biochemical studies and showing the lipoprotein 
aggregation and/or increased particle size, which is consistent with the non-
denaturing gel electrophoresis and SEC data. The two studies also provide a 
thorough biophysical and biochemical analysis of lipoproteins from DM2 patients. 
By using the approach to measure LDL and VLDL stability developed in the Gursky 
laboratory, we clearly showed that DM2 lipoproteins are distinct from their 
normolipidemic counterparts, not only biochemically but also because of their 
reduced structural and biochemical stability and increased pro-atherogenic 
potential.  
 
5.2 Unresolved questions and future studies 
5.2.1 Exploring conformational changes in apoB upon binding to heparin 
 To better understand the conformational changes of apoB after heparin 
binding, we probed bound LDL samples with apoB antibodies that were available 
to us. We chose antibodies directed against epitopes distributed along the primary 
structure of apoB, in an attempt to probe this very large protein at a wide range of 
locations. In these limited studies, I was not able to identify specific areas of apoB 
that underwent major structural changes upon heparin binding. In order to glean 
more detailed information, it would be beneficial to use antibodies close to or 






(1987). For this reason, using different antibodies, with specificities for regions 
closer to the heparin binding sites could help identify the apoB regions that 
undergo conformational changes upon heparin binding. A similar approach could 
be applied to explore potential structural differences on apoB in LDL particles 
differing in their size and biochemical composition such as the TG content. 
Additionally, the western blotting technique used in our preliminary studies 
may not be sensitive enough to identify specific conformational changes in apoB 
after heparin binding. Instead, one could use competitive a ELISA to analyze the 
conformation of apoB on native and bound LDL to improve our chances of 
detecting conformational changes in apoB. 
Ideally, these experiments should be complemented by studies of apoB 
interactions with other PGs, to verify that the key results obtained for heparin apply 
to other PGs including those found in the arterial wall. 
 
5.2.2 Exploring molecular details of VLDL - heparin interactions 
 We successfully analyzed the effects of heparin binding to LDL, but were 
not able to provide the same information for VLDL. There are several reasons for 
this, including large heterogeneity in the size (30-100 nm) and biochemical 
composition of VLDL particles as well as conformational heterogeneity in apoB on 
VLDL, which we do not yet fully understand. We know that the apoB conformation 
on LDL (diameter 20-24 nm) must be significantly different from that on VLDL, 






sites on apoB are exposed or blocked when apoB is on LDL or VLDL (Nestel et 
al., 1983, Huff & Telford, 1984). In fact, apoB on VLDL does not bind to heparin, 
either because of the different apoB conformation and/or because the binding sites 
are blocked by other VLDL proteins such as apoC-II (Nestel et al., 1983). Still, 
VLDL binds heparin via basic residues in other exchangeable apolipoproteins such 
as apoE and apoJ (Ji et al., 1997; de Silva et al., 1990; Olin-Lewis et al., 2002). 
How this binding affects VLDL stability, remodeling and, ultimately, maturation into 
LDL particles is unknown.  
Although the results of our studies of LDL-heparin interactions cannot be 
directly extrapolated to VLDL, I hypothesize that, similar to LDL, VLDL will be 
destabilized upon binding to heparin, which will likely result in biochemical and 
structural changes in LDL. I also speculate that these changes can potentially 
influence normal VLDL metabolism such as interactions with VLDL receptors and 
remodeling to LDL (non-atherogenic pathway), as well as the uptake of small (<25 
nm, compared to normal LDL =~26 nm) VLDL into the arterial intima (pathogenic 
pathway). It is also possible that VLDL-heparin interactions promote a more pro-
atherogenic VLDL profile. Because VLDL is a major lipoprotein class in plasma 
and an independent risk factor for atherosclerosis, the VLDL-heparin interactions 
are definitely worth investigating. 
The approach of chapter 4, which we used to explore LDL-heparin 
interactions, sets the basis for future studies of VLDL-heparin interactions. This 






such as apoE, apoJ, and phospholipase A2. Model studies of normolipidemic 
VLDL will be combined with studies of VLDL from diabetic patients. Also, in 
addition to heparin, other PGs will be explored. These future studies are expected 
to provide new insights into the effects of PGs on various aspects of VLDL 
metabolism, both normal and pathogenic, and how they are altered in diabetes.  
 
5.3   Towards determination of atomic structure of apoB on LDL 
 Despite the advances demonstrated in this dissertation, there are still 
unresolved questions regarding the structure-function relationship in apoB. For 
example, how does apoB conformation adapt to lipoprotein particles of different 
sizes? How does apoB on LDL interact with its major functional ligands, LDLr and 
HSPGs? What conformational changes in apoB are involved in these interactions?  
Answers to questions regarding apoB molecular interactions require a clear 
understanding of the atomic structure of apoB on LDL, which is currently lacking. 
Although a relatively homogeneous subfraction of plasma LDL has been 
crystallized by Laggner and Prassl’s team, the crystals did not diffract beyond very 
low resolution (Johs et al., 2006). The only currently available model of apoB is 
that of 17% of its N-terminal domain, which is based on the homology model of a 
related protein, lipovitellin, whose high-resolution structure has been solved by 
Banasak’s team (Jiang et al., 2005; Meininger et al., 1984).  Previous studies were 
able to provide a low-resolution model for apoB structure on LDL (Liu & Atkinson, 






that apoB wraps around the particle, with the N- and C- domains in close proximity 
to each other according to immuno-electron microscopy (Chatterton et al., 1991), 
and areas that are not contained by apoB are lipid-exposed (Aviram et al., 1988; 
Sommer et al., 1992; Liu & Atkinson, 2011). Additionally, important binding sites 
to LDLr and common apoB antibodies were mapped on this model; for example, 
the antibody Bsol7 used in this dissertation and the proposed LDLr binding site lie 
in the same region (Kumar et al., 2011).  
The main challenge in obtaining an atomic model of apoB on LDL is the 
conformational and compositional heterogeneity of LDL. This limited the quality of 
the crystallographic data recorded by Laggner’s team despite their best efforts to 
isolate a highly homogeneous LDL subfraction by SEC (Johs et al., 2006). Still, the 
fact that a relatively homogeneous LDL preparation has been crystallized was an 
important achievement. It suggests that, with the recent advances in high-
resolution cryo-EM techniques, the atomic structure of apoB on LDL may soon 
become available.  
 Once the apoB structure has been determined, one could use it to dock to 
heparin and thereby determine in detail potential modes of apoB-heparin 
interactions. Our laboratory has begun to utilize flexible molecular docking 
programs such as ClusPro to model the interactions of amyloid fibrils with heparin. 
The advantage of flexible docking is that the interacting partners are not rigid but 
have the flexibility to optimize their interactions.  In the future, one could apply a 







5.4 Implication for health and disease 
 We have provided links between molecular changes in lipoproteins and the 
effects that these changes have on particle longevity, interactions with each other 
and perhaps pathologies. When working on such a small biophysical scale, 
sometimes it is easy to lose sight of the big picture: addressing unknowns in 
harmful diseases, with hopes of working towards a cure. One major strength of this 
dissertation was providing evidence that diabetic patients undergoing glycemic 
control can rescue the integrity of lipoproteins to that of normolipidemic and 
normoglycemic particles. It has long been known that glycemic control improves 
overall health, but our study provides support for this effect at the molecular level.  
 Our results lay the groundwork for future studies to tease apart the 
intricacies of apoB. When a high-resolution structure of apoB becomes available, 
it can perhaps be combined with studies such as ours to help develop new 
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